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TRIM24 promotes mammary tumor development by upregulating
metabolic reducing power

Shucheng (Anna) Miao, B.S.
Advisory Professors: Michelle Barton, Ph.D.
and Guillermina Lozano, Ph.D.

Metabolic reprograming is an emerging hallmark of cancer cells. Changes in
cellular metabolism can contribute to cancer cell survival and tumor progression. Tripartite
motif-containing protein 24 (TRIM24) is an E3 ligase for p53, a nuclear receptor coregulator, and a histone reader. Over expression of TRIM24 correlates with poor overall
survival of breast cancer patients. Previously, our lab created a mouse model that
conditionally over-expresses (COE) TRIM24 protein in mammary epithelia (Trim24COE)
and develops carcinosarcoma or metaplastic mammary tumors (70% of all Trim24COE
tumors), a rare and aggressive triple-negative subtype called metaplastic TNBC in
humans (MpBC). RNA-sequencing revealed that Trim24COE mouse mammary tumors
have upregulated glycolysis and epithelial-to-mesenchymal transition (EMT). Trim24COE
carcinosarcoma cell-derived spheroids showed irregular, poorly differentiated structures
that were more invasive compared to spontaneous, control MMTV-cre mammary tumorderived spheroids. Using
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C6-glucose/glutamine tracing, we found Trim24COE spheroids

recapitulated some of the metabolic features of Trim24COE carcinosarcomas like
upregulated glycolysis and exhibited aberrantly upregulated antioxidant defenses. We
found Trim24COE spheroids exhibited low intracellular and mitochondrial ROS, an
increased NADP(H) pool, and were more resistant to oxidative stress. Quantitative
reverse-transcriptase polymerase chain reaction (qRT-PCR) and immunoblotting
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validated that enzymes of one-carbon metabolism and de novo glutathione synthesis
pathways were upregulated in Trim24COE spheroids and that upregulation was depended
on TRIM24 over expression. NRF2 is a key regulator of cellular antioxidant response and
often found over expressed in many different types of cancers. Nrf2 mRNA level and NRF2
protein expression were both upregulated in the Trim24COE spheroids and knocking down
TRIM24 significantly decreased Nrf2 expression as well as NRF2-regulated gene
expression. Metabolic inhibitors that target enzymes in one-carbon metabolism and de
novo glutathione synthesis effectively decreased Trim24COE spheroids viability. The effect
of PHGDH inhibitor CBR5884, GLS inhibitors CB839, and GCLC inhibitor was enhanced
with TRIM24 knock-down, indicating that TRIM24 plays a critical role in oxidationreduction (REDOX)-related cell survival.
Here, with metabolomic studies, we uncovered the potential metabolic vulnerabilities in
Trim24COE MpBC spheroids. TRIM24 over expression led to upregulated production of
reducing equivalents which further reduce oxidative stress and increase antioxidant
defense in Trim24COE spheroids. Targeting TRIM24 and the corresponding metabolic
enzymes in combination could shed light on potential strategies for inhibiting tumor
progression of TRIM24-overexpressing MpBC. The work described here supports further
investigations of these pathways in MpBC, for which no targeted therapies exist.

vii

Table of Contents
Approval Sheet…………………………………………………………………. i
Title Page………………………………………………………………….….… ii
Dedication………………………………………………………………………. iii
Acknowledgements……………………………………………………………. iv
Abstract…………………………………………………………………………. vi
Table of Contents…………………………………………………………….... viii
List of Figures………………………………………………………………...... ix
List of Tables…………………………………………………………………… xiii
List of Abbreviations………………………………………………………...…. xiii
Introduction……………………………………………………………………….1
Materials and Methods…………………………………………………………. 6
Results…………………………………………………………………………… 18
Discussion……………………………………………………………………..... 68
Appendix …………………………………………………………………….... 77
References…………………………………………………………………….... 82
Vita………………………………………………………………………………. 103

viii

List of Figures
List of Figures
Figure 1: TRIM24 protein structure and domains.………...………………………………….4
Figure 2: Generation of mammary spheroids culture. .……...……………………...……….7
Figure 3: Workflow of isotope tracing (LC/IC- HRMS)...……….……………………..……10
Figure 4: Generation of Trim24COE mouse line. .…………….………………...……………19
Figure 5: Overexpression of TRIM24 in Trim24COE spheroids confirmed by western
blot ..……….….….….…….….…….….…….….………..……………………………….……20
Figure 6: Overexpression of TRIM24 in Trim24COE spheroids confirmed by IF staining….21
Figure 7: Morphology of Trim24COE spheroids. …………………………..………………….23
Figure 8: Knock- down of TRIM24 in shTrim24-64 and shTrim24-897 spheroids confirmed
by western blots and IF staining. ……………………..……………………………………….24
Figure 9: Quantification of spheroid diameters showed TRIM24-dependent spheroid
size……………………………………………………………………………………………….26
Figure 10: Quantification of spheroid invasion percentage showed TRIM24-dependent
invasiveness. ……...………………………………………………………….…..…………….26
Figure 11: Western blots of EMT markers in Trim24COE spheroids……………………...….28
Figure 12: Different EMT transcription factor mRNA expression across Trim24COE spheroid
lines………………………………...…………………………...……………………………….29
Figure 13: Western blots of c-MYC and their quantification showed TRIM24-dependnet cMYC at protein level. …………………..…………...…………………………..……..……….30
Figure 14: Western blots and their quantification showed different BCSCs marker levels
in Trim24COE, shCT-897 and shTrim24-897 spheroids………..……………..……..……….31
Figure 15: IF staining of K8 (luminal epithelial cell) and K14 (basal epithelial cell) in
Trim24COE spheroids………………………………….………………….……..……..……….32
Figure 16: IF staining of K8 (luminal epithelial cell) and K14 (basal epithelial cell) in shCT897 and shTrim24-897 spheroids. ………..……..……..…………………………………….33

ix

Figure 17: Western blot of K8 (luminal epithelial cell) and K14 (basal epithelial cell) in
shCT-897 and shTrim24-897 spheroids.……..…………..…….…………………………….34
Figure

18:

RNA

sequencing

data

revealed

heterogeneity

in

Trim24COE

spheroids………………………………………………………………………………………..35
Figure 19: CellROX staining showed low intracellular ROS in Trim24COE spheroids
compared to the MMTVCRE-823 control……….……..……..…….…………………………….36
Figure 20: Low intracellular ROS levels in spheroids were dependent upon TRIM24
overexpression………….......……….……………………..…….…………………………….37
Figure 21: Intracellular ROS increased in MMTVCre-823 spheroids after 24 hours of H2O2
treatment but not in Trim24COE spheroids….……………..…….…………………………….38
Figure 22: Intracellular ROS increased in shTrim24-897 spheroids after 24 hours of H2O2
treatment but not in shCT spheroids. ……….……………………..…….……………………39
Figure 23: MitoSOX staining of mitochondrial ROS after 24 hours of H2O2 treatment did
not change in MMTVCre-823 or Trim24COE spheroids...………………………..…….………...41
Figure 24: Trim24COE spheroid showed decreased overall response to Seahorse Mito
Stress Test and TRIM24 knock down further decreased the responses…………………..42
Figure 25: Total NADP(H) and reduced NADPH levels were upregulated in Trim24COE
spheroids while decreased upon TRIM24 knock down. ……..………………..……………43
Figure 26:

13

C6-glucose isotope tracing revealed increased glycolysis diversion to PPP

shunt and 1C metabolism in Trim24COE-897 spheroids………….…………………………….44
Figure 27: Western blots of PPP and 1C metabolism pathway showed increased enzyme
levels in Trim24COE spheroids TRIM24-dependent enzyme levels in 1C metabolism…….45
Figure 28: CTG viability assays showed PHGDH inhibitor CBR5884 decreased Trim24COE
spheroid viability; the decrease in viability was enhanced upon TIRM24 knock down...…47
Figure 29: Total NADP(H) and reduced NADPH assays revealed decreased reducedNADPH level in Trim24COE spheroids after treated with CBR5884…………………………47

x

Figure 30: 3PG supplement rescued Trim24COE spheroids viability but failed to rescue up
TRIM24 knock down……………………………………………………………………………48
Figure 31:

15

C5-glutamine tracing of Trim24COE spheroids and GSH/GSSG ratio assay

revealed increased reduced glutathione level in Trim24COE spheroids………...…………..49
Figure 32: Western blot quantification of enzyme levels showed increased glutaminolysis
pathway and de novo GSH synthesis pathway in Trim24COE-897 spheroids……….……….50
Figure 33: Western blot quantification showed downregulated enzymes in glutamate
metabolism pathway and de novo GSH synthesis pathway in shTrim24-897 spheroids...51
Figure 34: GLS inhibitor CB839 inhibits the conversion of glutamine to glutamate…….…53
Figure 35: CB839 treatment for 48 hours increased intracellular and mitochondrial ROS
levels in Trim24COE spheroids. ……………………………………………..………………….54
Figure 36: Viability of Trim24COE spheroids was decreased after 48-hours CB839 treatment;
the drug effect was enhanced by TRIM24 knock down………………………...……………55
Figure 37: Total NADP(H) and NADP+/NADPH ratio assay of Trim24COE spheroids,
showed increased NADP+ abundance after CB839 treatment…………..…………………56
Figure 38: CTG viability assay showed BSO treatment had additive effect with TRIM24
knock down. ………………………………………………..………………..………………….57
Figure 39: Total NADP(H) levels were increased in Trim24COE-567 and Trim24COE-64
spheroids but not Trim24COE-897 spheroids……...……….………………..………………….58
Figure 40: CTG viability assay showed different responses to combined GSH synthesis
inhibitor treatment in Trim24COE spheroids, shCT-897 and shTrim24-897...………..…….59
Figure 41: CTG viability assay showed resistance to H2O2 was TRIM24 dependent….....61
Figure 42: Usage of reduced NADPH in response to H2O2 treatment was impaired by
TRIM24 knock down...……………..……………………………………………………….….62
Figure 43: Nrf2 and its target genes mRNA expression in Trim24COE spheroids was
induced by 24-hour 1mM H2O2 treatment…………………….……………………….……...64

xi

Figure 44: Nrf2 and its target gene mRNA expression was decreased upon Trim24 knock
down but induced after 24-hour 1mM H2O2 treatment in shTrim24-897...…………...…….65
Figure 45: Western blots and their quantification of NRF2 showed TRIM24-dependent
NRF2 protein level…...………………………………………………………...……………….66
Figure 46: Western blot quantification showed NRF2 downstream pathway enzyme levels
were increased in Trim24COE spheroids after 24-hour 1mM H2O2...……………..…….…...67
Figure 47: Western blot quantification showed NRF2 downstream pathway enzyme levels
were downregulated in shTrim24-897 spheroids compared to shCT-897 after 24-hour
1mM H2O2……………………………………………………………………………………….68

xii

List of Tables
Table 1: Summary of rewired glycolysis and 1C-metabolism in Trim24COE spheroids and
shCT/shTrim24-897 spheroids ……………………………………………………........74

Table 2: Summary of rewired GSH synthesis pathway in Trim24COE spheroids and
shCT/shTrim24-897 spheroids ……………………………………………………........74

Table 2: Summary of NRF2-regulated response under oxidative stress in Trim24COE
spheroids and shCT/shTrim24-897 spheroids………………………………………… 75

Appendix
List of antibodies…………………………………………………………………….... 71
List of primers……………………………………………….……………………….... 73
List of drugs and reagents……………………………………….………………….... 75

xiii

List of Abbreviations
3PG/2PG

3-phosphoglycerate/3-phosphoglycerate

AKT

Protein kinase-B

ASCT

Alanine-serine-cysteine transporter

ASNS

Asparagine synthase

ARE

Antioxidant response element

ATP

Adenosine triphosphate

BCA

Bicinchoninic acid assay

BSCs

Breast cancer stem cells

BSO

Buthionine sulfoximine

Bromo

Bromodomain

cDNA

Complementary deoxyribonucleic acid

COE

Conditionally overexpressed

CTG

CellTitor-Glo® viability assay

CTF

CellTitor-FlourTM viability assay

CUL

Cullin

DMSO

Dimethyl sulfoxide

DNA

Deoxyribonucleic acid

DMEM

Dulbecco's Modified Eagle Medium

ECAR

Extracellular Acidification Rate

EDTA

Ethylenediaminetetraacetic acid

EMT

Epithelial-mesenchymal transition

ER

Estrogen receptor

ERK

Extracellular signal regulated protein

FBS

Fetal bovine serum

FCCP

Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone

xiv

G6PD

Glucose-6-phosphate dehydrogenase

GCL

Glutamate-cysteine ligase

GluD

Glutamate dehydrogenase

GluL

Glutamine synthase

GLS

Glutaminase

GPX

glutathione peroxidase

GSH

Reduced glutathione

GSS

glutathione synthase

GSSG

Oxidized glutathione

GSR

Glutathione reductase

GST

Glutathione transferase

KLF4

Kruppel-like factor 4

HER2

Epidermal growth factor receptor 2

HRMS

High-resolution mass spectrometry

H2O2

Hydrogen peroxide

IF

Immunofluorescence

iHMECs

Isogenic human mammary epithelial cells

K8/K14

Cytokeratin 8/ Cytokeratin 14

KEAP

Kelch-like associated protein

LC/MS

Liquid chromatography/mass spectrometry

MAPK

Mitogen-activated protein kinase

MDACC

M.D. Anderson Cancer Center

MpBC

Metaplastic breast cancer

mRNA

Messenger ribonucleic acid

mtDNA

Mitochondrial deoxyribonucleic acid

MTHFD

Methylenetetrahydrofolate dehydrogenase

mTOR

Mammalian target of rapamycin

xv

NADPH

Nicotinamide adenine dinucleotide

NOX

Nicotinamide adenine dinucleotide oxidase

NRF2

Erythroid2-related factor

O2-

Superoxide anion

·OH

Hydroxyl radical

OCR

Oxygen consumption rate

OXPHOS

Mitochondrial respiration or oxidative phosphorylation

p53

Tumor protein p53

P5CDH

Delta-1-pyrroline-5-carboxylate dehydrogenase

PGD

6-phosphogluconate dehydrogenase

PHGDH

Phosphoglycerate dehydrogenase

PFA

Paraformaldehyde

PGK

Phosphoglycerate kinase

PHD

Plant homeodomain

PI3K

Phosphoinositide 3-kinase

PPP

Pentose phosphate pathway

PR

Progesterone receptor

PRODH

Proline dehydrogenase

PSAT

Phosphoserine aminotransferase

PYCR

Pyrroline-5-Carboxylate Reductase 1

Redox

Reduction-oxidation

TALDO

Transaldolase

TCA

Tricarboxylic acid cycle

TNBC

Triple negative breast cancer

Trim

Tripartite motif containing family of proteins

TWIST

Twist Basic Helix-Loop-Helix Transcription Factor

qRT-PCR

Quantitative Real-time polymerase chain reaction

ii

ROS

Reactive oxygen species

RNA

Ribonucleic acid

SHMT

Serine hydroxymethytransferase

shRNA

Short hairpin ribonucleic acid

SMA

Smooth muscle actin

SNAI

Snail Family transcriptional repressor

SOX

SRY-Box transcription factor

siRNA

Small interfering ribonucleic acid

ZEB

Zinc Finger E-Box Binding Homeobox 1

iii

Introduction
One hundred and one years ago in 1920, pioneering biochemistry researcher Otto
Warburg discovered aerobic glycolysis in tumor tissues cultured in vitro. This finding
revolutionized the field by linking cancer biology to metabolism [1, 2]. His observation
became known as the Warburg Effect, which describes the high rate of glucose uptake,
glycolysis and lactate secretion exhibited by cancer cells under non-hypoxic conditions,
even with a high concentration of oxygen [3]. The Warburg effect was once considered a
hallmark of aggressive cancer cells, but later was found in highly proliferative nontransformed cells [4]. Historically, aerobic glycolysis was thought to be a consequence of
impaired mitochondrial respiration [5] as hyperactive glycolysis eliminates carbon sources
from the TCA cycle. However, in the past decades, the origin of aerobic glycolysis has
been questioned as more studies reveal that mitochondria in cancer cells are still
functional with relatively lower activity [6].
Increased

glucose

uptake

and

glycolysis

allow

cancer

cells

to

feed

macromolecular synthesis pathways, other than the mitochondrial citric acid cycle (TCA
cycle). These pathways include pentose-phosphate pathway (PPP) that produces ribose
ring for DNA/RNA synthesis and reducing agent NADPH; serine-glycine-one-carbonmetabolism (1C metabolism) that produces folate, NADPH, and glutathione synthesis
substrate; and the hexosamine pathway that produces metabolites for protein
glycosylation [2]. Nicotinamide adenine dinucleotide phosphate (NADPH) is a major
reducing equivalent in antioxidant systems such as glutathione (GSH) and catalase, and
it plays a critical role in the maintenance of enzyme-catalyzed reduction-oxidation (Redox)
balance in the cells [7].
Redox is a principle biochemical reaction in all living cells by which oxidative atoms
are exchanged. Oxygen (O2) is an essential molecule for mammalian cells to produce
adenosine triphosphate (ATP) through mitochondrial respiration also known as oxidative
phosphorylation (OXPHOS). O2 is a relatively unreactive molecule, however, incomplete
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reduction of O2 will lead to the formation of reactive oxygen species (ROS). ROS is a
collective term for hydrogen peroxide (H2O2), hydroxyl radical (·OH) and superoxide anion
(O2-) [8]. They are mainly produced by the mitochondrial electron transport chain (ETC)
during oxidative respiration, peroxisomes through fatty acid β-oxidation, and endoplasmic
reticulum through oxidation of proteins [9]. ROS are chemically highly reactive and they
can cause structural or functional damage to proteins and lipids, as well as DNA strand
breaks to potentially induce genomic instability [10].
ROS had been thought to be a deleterious metabolite until the 1990s. Studies of
the past decades set the stage for the role of ROS in cellular signaling cascades and
driving tumorigenesis [11]. Low doses of ROS (around 1 µM) are capable of stimulating
cellular adaptation and proliferation; however, as ROS level increases, cell death signaling
pathways such as apoptosis or ferroptosis are initiated [12]. ROS are both initiators and
promoters of cancer. During the transformation process, activation of oncogenes, loss of
tumor suppressor genes, and mutations in mitochondrial DNA (mtDNA) lead to a surge in
ROS level in cells [13]. This allows activation of phosphoinositide 3-kinase/protein kinaseB/mammalian target of rapamycin pathways (PI3K/AKT/mTOR), mitogen-activated
protein kinase/extracellular signal regulated kinase (MAPK/ERK) and nuclear factor κB
(NFκB) pathways [11, 12, 14]. Continuously increased ROS further can induce more
mutations in cancer cells and promote tumor growth, resistance to chemotherapy and
metastasis [8].
According to the Global Cancer Observatory(GCO), breast cancer (BC) had the
highest incidence worldwide in 2020, with approximately 2.2 million diagnosed cases [15].
It is the most common malignancy and also the top cause of cancer-related deaths among
women [16]. BC is a highly heterogeneous disease and is characterized into three major
subtypes in the clinic: estrogen and/or progesterone receptor (ER/PR)-positive, epidermal
growth factor receptor 2 (ERBB2/ HER2)-positive, as well as triple-negative breast cancer
(TNBC) which lack of ER, PR and HER2 [17]. At a molecular level, BC is divided into four

2

subtypes based on the gene expression signatures. In order of better clinical prognosis to
worse prognosis, they are luminal A (ER-positive and/or PR-positive, HER2-negative),
luminal B (ER-positive and/or PR-positive, HER2-positive), HER2-enriched (ER-negative
and PR-negative, HER2-positive) and basal-like (ER-negative, PR-negative, and HER2negative) breast tumors [18]. The presence of these hormone receptors ER, PR, and
HER2 determines therapeutic strategies.
Without hormone receptors as molecular targets, TNBC patients have poorer
clinical outcomes compared to other subtypes [19]. TNBC is associated with high tumor
histologic grade, heterogeneity, aggressive phenotype and high metastatic rate [19-21].
Although standard treatment chemotherapy like epirubicinad and capecitabine [22]
provides some benefit for the TNBC patient, the high rate of recurrence and resistance to
chemotherapy are still major problems [19]. Metabolic reprogramming is an emerging
hallmark of cancer cells, which may offer potential vulnerabilities that may lead to new
therapeutic approaches [12]. Major metabolic pathways, primarily glucose, glutamine,
serine and fatty acid metabolism are rewired to support anabolism, catabolism and redox
regulation in TNBC [23, 24]. Alterations of these metabolic pathways may reflect their
regulation by upstream signaling pathways, such as RTK/KRAS, PI3K/AKT/mTOR, p53
and c-Myc which are commonly aberrant in TNBC [25].
Metaplastic breast cancer (MpBC) is a rare and less studied TNBC subtype,
representing 0.2%-5% of all breast cancers [26]. It is identified by the presence of both
epithelial features (carcinoma) and mesenchymal/stromal cell characteristics (sarcoma)
[27]. With dismal clinical outcomes even worse than other subtypes of TNBC, MpBC is
very aggressive and highly metastatic. These characteristics are attributed to highly
expressed epithelial-to-mesenchymal transition (EMT) signature genes and tumor stem
cell marker gene expression [26]. Previous work from our lab revealed that, TRIM24 was
overexpressed in MpBC patients and high TRIM24 levels also correlated with poor
prognosis and overall survival of patients [28]. TRIM24 is over expressed in multiple
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cancers [29]. It has a RING-domain E3 ligase for p53 degradation, binds and ubiquitinates
p53 and keeps p53 level low at steady state. TRIM24 and p53 interaction forms an
autoregulatory loop: when DNA damage accumulates in the cells, degradation of p53 by
TRIM24 is inhibited which leads to increased p53 level and also results in increased
TRIM24 transcription. Higher TRIM24 level again degrade p53 through ubiquitylation and
negatively regulates p53 level in the cells [30]. In contrast, TRIM24 depletion in human
breast can cells induces spontaneous apoptosis in a p53-dependent manner [31]. TRIM24
also has a LXXLL domain for binding nuclear receptor ER; and plant homeodomain
(PHD)/bromodomain (Bromo) histone reader of unmodified H3K4(H3K4me0) as well as
acetylated H3K23 (H3K23ac) [28, 30, 31] (Figure 1). Studies from our lab showed that
aberrant expression of TRIM24 in isogenic human mammary epithelial cells (iHMECs)
induces malignant transformation and promotes glycolytic and tricarboxylic acid (TCA)
gene upregulation [32]. However, it remains unclear how TRIM24 over expression
reprograms metabolic pathways that contribute to survival and proliferation of TRIM24over expressing breast cancer cells.

Figure 1: TRIM24 protein structure and domains.
TRIM24, 116KD, is a multi-domain protein. The RING domain ubiquitinates and
degrades phosphorylated p53; the B-boxes (B-B) are zinc finger domains; the coiled-coil
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domain (C-C) is required for hetero-oligomerization with other TRIM family proteins; The
LXXLL motif interacts with nuclear hormone receptors; PHD and Bromo domains are
histone readers which recognize demethylated H3K4 and acetylated H3K23. Overall,
TRIM24 recruit ER to chromatin and activate ER-targeted gene expression in breast
cells.
TRIM24 over expression plays a causal role in cancer cell proliferation, tumor
initiation and progression [28, 32]. To further study the mechanism and consequences of
TRIM24 over expression, our lab generated a mouse model that conditionally
overexpresses (COE) TRIM24 protein in mouse mammary epithelia (Trim24COE), which
resulted in development of carcinosarcoma or metaplastic mammary tumors. Global gene
expression analysis revealed that Trim24COE mammary tumors exhibit highly activated
glycolysis, EMT, and cMET-PI3K-mTOR pathways [33]. Glycolysis, as the most
upregulated pathway in Trim24COE tumors, reflects a typical Warburg effect that also fuels
multiple metabolic branches, such as PPP and 1C metabolism for NADPH production. As
an essential reducing equivalent, NADPH levels are closely associated with redox balance
in cells. Thus, I hypothesized that TRIM24 promotes breast cancer progression through
rewiring redox regulation. To test this hypothesis, we performed metabolomic studies
using three-dimensional mammary spheroids derived from mouse mammary MpBC cells,
with the goal of understanding redox regulation in MpBC tumor model cells to reveal
potential metabolic vulnerabilities.
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Methods

Embedded spheroid culture
Metaplastic breast cancer primary cell lines were generated from mouse metaplastic
breast tumors as our recently published paper described [33]. Adherent cells were
trypsinized (0.05% Trypsin, Gibco, 25300120) and resuspended with breast cancer
spheroids medium. The spheroid culture medium consists of DMEM/F12 (Gibco 11330032), 10% FBS (Gemini Bioproducts, 100-106), 100 U/mL Penicillin/Streptomycin (Gibco,
15140122), 1x B27 supplement (Gibco, 17504044), 5 µg/mL Insulin (Sigma I-5500), 1
µg/mL Hydrocortisone (Sigma, H0888), and 10 ng/mL EGF (ThermoFisher, PHG0310).
Matrigel Matrix for organoid culture (Corning, 356255) was thawed at 4oC and kept on ice.
Tissue culture-treated 24-well plates (Corning, 3524) needed to be coated with Matrigel
to prevent monolayer formation, the coated plates were then placed in 37°C and 5% CO2
incubator for the Matrigel to solidify. The plating procedure was modified from the
previously published protocol [34] (Figure 2). Approximately 2500 cells were mixed in 50
µL Matrigel and plated on top of the Matrigel coating with cold pipette tips. The plate was
put back to the 37°C and 5% CO2 incubator for 15 minutes. Once the Matrigel dome
solidifies, 1 mL spheroid culture medium was added to each well and the medium was
changed every 3 to 4 days.
To retrieve the spheroids for subsequent functional studies, the spheroids culture medium
was removed and the Matrigel domes that contained embedded spheroids were gently
washed with room temperature PBS (Hyclone, SH30256.01). 500 µL cold Cell Recovery
Solution (Corning, 354253) was added to each well and kept on ice for 15 to 20 minutes
to dissolve the Matrigel. The spheroids were collected in 1.5 mL tubes from each well and
centrifuge at 4°C and 500 rpm for 5min. Cell pellets were washed with cold PBS three
times and the pellets can be stored at -80°C.
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Figure 2: Generation of mammary spheroids culture.
(Figure made in BioRender.com)

Immunofluorescence staining
Whole-culture immunofluorescence staining was performed as previously described [34,
35]. 8-chamber cover glass slide (Lab-Tek II, 155409) was coated with pre-thawed 10 µL
Matrigel (Corning, 356255) per chamber. The coated slide was placed at room
temperature for 15 minutes. After the coating gel was solidified, mixed approximately 2000
cells with 50 µL Matrigel and plated it on top of the coating. The slide was put into the
37°C and 5% CO2 incubator for 15 minutes, then 500 µL complete spheroid culture
medium was added to each well. On day 4 of culturing, the spheroids were fixed with 200
µL/well 4% paraformaldehyde (Sigma, P6148) at room temperature for 10 to 15 minutes.
Each well was then washed with PBS (Hyclone, SH30256.01) twice. 0.5% Triton X-100
(Fisher Bioreagents, BP151-500) was used to permeabilize the samples, by adding 200
µL/well to each well at room temperature for 30 minutes. After removing the 0.5% Triton
X, the samples were immediately blocked with 10% FBS for 2 to 3 hours at room
temperature. Primary antibodies (Appendix 1) were diluted to the 1:200 with 10% FBS and
incubated with the sample at 4°C overnight. After removing the primary antibodies, the
samples were washed with 10% FBS three times, 10 minutes each time at room
temperature. Secondary antibody Alexa Fluor 647 Goat anti-mouse IgG (Invitrogen,
A21236) or Alexa Flour 488 goat anti-rabbit IgG (Invitrogen, A11034) were diluted to 1:500
with 10% FBS. The samples were incubated with the secondary antibodies for 1 to 2 hours
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at room temperature. After the removal of secondary antibodies, the samples were
washed with PBS for three times at room temperature, 10 minutes each time. Finally, the
samples were stained with 1:500 DAPI, diluted with PBS, for 20 minutes at room
temperature, followed by three 10 minutes wash with PBS. Olympus Fluoview 1000
confocal microscopy was used to take the z-stacked images of the spheroids. Z-stacked
images were assembled and with Fiji, as well as the 3D reconstruction.

Invasion analysis
About 3000 cells were plated in 24-well plates (Corning, 3524) coated with Matrigel,
following the procedure described above. On day 4, brightfield images of ten randomly
selected areas were taken from each well. With Celigo Image Cytometer (Nexcelom
Biosciences), invasion area could be scanned and quantified. With an image processing
software Fiji, fifteen spheroids were randomly selected and the number of invasive/noninvasive spheroids were counted by hand and the invasion percentage was calculated
(invasion % = # of invasive spheroids/# of total spheroids). Ten image fields were
quantified from each cell lines and an average invasion percentage was calculated.

Cellular ROS and mitochondrial ROS staining
Reactive oxygen species (ROS) level was measured with CellROX® Orange (Life
Technologies, C10443), CellROX® Deep Red Reagents (Life Technologies, C10422), and
MitoSOXTM (Molecular Probes, M36008) following the manufacturer’s protocol. Spheroids
were stained with 1:500 CellROX or 1:1000 MitoSOX reagent in an 8-chamber cover glass
slide (Lab-Tek II, 155409), with DAPI (1:300 dilution) as a counterstain. The spheroids
were incubated with the ROS stain in 37°C and 5% CO2 incubator for 1 hour. PBS was
used to wash the slides three times. Fluorescent signals were detected with Olympus
Fluoview 1000 confocal microscopy, and Fiji was used to quantify the signal intensity.
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Cell viability assay
Spheroid viability was assessed using CellTiter-Glo® Luminescent Cell Viability Assay
(CTG) (Promega, G7570) and CellTiter-FluorTM Cell Viability Assay (CTF) (Promega,
G6080), following the manufacturer’s protocols. After adding the reagent directly to the
spheroid culture, the samples were put on a horizontal rocker for 15 minutes at room
temperature and protected from light. Luminescent (CTG) or fluorescence (CTF) indicating
cell viability was measured with FLUOstar Omega plate reader.

LC/IC- HRMS analysis of polar metabolites
To assess the incorporation of carbon from glucose or glutamine into glycolysis pathway,
Pentose Phosphate Pathway (PPP) and intracellular tricarboxylic acid (TCA) cycle,
metabolites extracts from cell lysate were prepared and analyzed by high-resolution mass
spectrometry (HRMS). Spheroids embedded in Matrigel were harvested on Day 4 of
culturing from 10 cm dishes (about thirty 50 µL Matrigel domes per plate) in triplicate. Cells
were washed with glucose-free or glutamine-free medium then cells were incubated in
fresh complete medium containing 11.1 mM
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C6-Glucose for 6 hours; or 2 mM
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C5-

Glutamine for 24 hours. Spheroid-containing Matrigel domes were washed with cold PBS
and 5 mL Cell Recovery solution (Corning, 354253) was added to reach plate, following
by 15 minutes incubation at 4°C. After the Matrigel dissolved, spheroids were transferred
to 15 mL tubes and pellets were washed with PBS twice (Figure 2). Metabolites were
extracted with cold 80% methanol with 0.1% ammonium hydroxide. Cell lysates were
centrifuged at 17,000 g for 5 min at 4°C. The supernatants were then transferred to clean
tubes, followed by evaporation under nitrogen until the samples were complete dry. Dried
samples were then reconstituted with deionized water, then 5 μL was injected into a
Thermo Scientific Dionex ICS-5000+ capillary ion chromatography (IC) system that
contains a Thermo IonPac AS11 250×2 mm 4 μm column (ThermoFisher, 078035) for
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glycolysis and TCA cycle metabolites analysis. IC flow rate was 360 µL/min at 30°C and
the gradient conditions were as follows: started with 1 mM KOH, increased to 35 mM at
25 minutes, then to 99 mM at 39 minutes, held at 99 mM for 10 minutes. The total duration
of the experiment took 50 minutes. Methanol was administered by an external pump and
combined with the eluent via a low dead volume mixing tee, in order to assist the
desolation for better sensitivity. Metabolite data was acquired with a Thermo Orbitrap
Fusion Tribrid Mass Spectrometer under ESI negative mode.
To analyze amino acids, samples were diluted in 90% acetonitrile containing 1% formic
acid, then 15 μL sample was injected into a Thermo Vanquish liquid chromatography (LC)
system containing an Intrada Amino Acid 2.1 x 150 mm column (Imtakt, WAA25) with 3
µm particle size. Mobile phase A (MPA) was acetonitrile with 0.1% formic acid and mobile
phase B (MPB) was 50 mM ammonium formate. The flow rate was set to 300 µL/min at
35°C, and the gradient conditions were: 15% MPB in the beginning, increased to 30%
MPB at 20 min, then increased to 95% MPB at 30 min, held at 95% MPB for 10 minutes,
returned to initial conditions followed by equilibration for 10 minutes. The total run time
took 50 minutes and the data was acquired by Thermo Orbitrap Fusion Tribrid mass
spectrometer under ESI positive ionization mode, at a resolution of 240,000. Then the raw
data was imported to Thermo Trace Finder software for further analysis. The fractional
abundance of each isotopologue was determined by the peak area of the corresponding
isotopplogy normalized by the sum of all isotopoloy areas.

Figure 3: Workflow of isotope tracing (LC/IC- HRMS).
(Figure made in BioRender.com)
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Protein extraction and Western Blotting
Spheroids embedded in Matrigel were collected following the protocol described above.
150 µL or 200 µL 1% SDS was added to the cell pellets, depended on the size of the cell
pellets. The protein lysate was homogenized by sonification at 40% power for 5 seconds,
repeated three times. The debris was removed through centrifugation at 14000 rpm for 15
minutes at 4°C. Protein concentration was estimated by Pierce™ BCA Protein Assay Kit
(ThermoFisher, 23227) and diluted to the desired concentration with 1% SDS. 5x SDS
loading dye was added to the normalized lysate then separated by electrophoresis on a
1.5mm 10% SDS-PAGE gel. Resolved proteins were transferred to nitrocellulose
membrane through Trans-blot®Turbo™ Transfer System (BioRad, 1704150) as the
manufacturer instructed. The membranes were stained with Ponceau S solution (Fisher
Scientific, NC9099742) to confirm the transfer of protein bands. 3% milk was made by
adding 3g of milk powder to 100 mL 1X TBST and it was used to block the membrane at
room temperature, rocking for 1 hour. Primary antibodies (Table S2) was diluted according
to the manufacturer’s recommendation with 3% milk and incubated with the membrane at
4°C, rocking overnight. The membranes were then washed with 1X TBST for 10 minutes,
repeated 3 times, followed by secondary antibodies (Goat anti-Mouse, Invitrogen 35518;
Goat anti-Rabbit, Invitrogen SA5-10036) incubation at room temperature for 1 hour. After
three washes with 1X TBST for 10 minutes and two washes with 1X TBS, the membranes
were imaged with the ChemiDoc™ Imaging System (BioRad, 12003153)

RNA Extraction, reverse transcription and RT-qPCR
To collect spheroids embedded in Matrigel, the desired amount of cold Cell Recovery
Solution (Corning, 354253) was used following the procedure described above. 300 µL
Trizol was added to the spheroid pellets and stored in -80°C. To extract RNA, 300 µL 100%
ethanol was added to the lysate and mixed well. Zymo-Spin IICR Column (Zymo Research,
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C1078) was used to collect the RNA referring to the manufacturer’s instruction. The
samples were transferred to the spin column, and the flow-through was discarded. 400ul
of RNA Wash Buffer (Zymo Research, R1003) was added to the column followed by
centrifugation. 80 µL of DNase I treatment was prepared from 5 µL DNase I (Zymo, E1010),
and 75 µL DNA Digestion Buffer (Zymo, E1010) and then the mixture was added to the
spin columns followed by room temperature incubation for 15-minutes. After centrifugation,
400 µl of Direct-zol RNA PreWash (Zymo Research, R2050) was added to the spin
columns and centrifuged. Flow-through was discarded and the washing step was repeated.
700 µL RNA Wash Buffer was then added to the spin column, centrifuged and the flowthrough was discarded. To remove excess washing buffer, spin columns were transferred
to new collection tubes and centrifuged for 2 minutes. The spin columns were transferred
to new 1.5 mL Eppendorf tubes and 30 µL of DNase/RNase-Free Water was added to the
spin columns and incubated at room temperature for 5 minutes before centrifugation. The
eluted RNA was then added back into the spin column and centrifuged again. The eluted
RNA was then analyzed via Nanodrop for quality and concentration of RNA yield.
The cDNA was made using the iScript Reverse Transcription Supermix (BioRad, 1708841)
as per the manufacturer’s guidance. Thermocycler was used to carry out the reverse
transcription with the setting of: 25°C for 5 minutes, 46°C for 20 minutes 96°C for 1 minute.
The cDNA product was diluted to 1:20 with RNase-free water for real-time quantitative
PCR. All RT-qPCR primers were designed with the primer picking tool Primer-BLAST and
Mouse Genome Informatics Database Ensemble on the NCBI website (Table S3). Stock
solutions of primers were diluted at a concentration of 100Um in RNase-free sterile water.
Working primer dilutions were made of a 1:10 of the stock primer solution. Master mix for
qPCR was made with 5 µL Syber Green (BioRAD, 1725270), 0.05 µL of the forward or
reversed primer, 1.9 µL RNase-free sterile water, and 3 µL cDNA of each sample. RTqPCR reactions were performed with the these conditions: 95°C holding for 5 minutes,
95°C for 30 seconds, 55°C to 60°C for 30 seconds which depends on primer sets’
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annealing temperature, and 72°C elongations for 30 seconds, repeat to step 2 for 40
cycles. 18S ribosomal RNA was used as a housekeeping gene for normalization.

Oxygen Consumption Assays (Seahorse)
Seahorse XFe96 Extracellular Flux Analyzer (Aligent Technologies) was used to quantify
the cellular oxygen consumption rate (OCR). 2D cells were seeded at 10,000 cells per
well in a 96-well cell culture plate (Agilent Technology, 102340-100) with 200 µL/per well
DMEM (Corning, 10-017-cv) which supplemented with 10% FBS (Gemini Bioproducts,
100-106) and 100 U/mL Penicillin/Streptomycin (Gibco, 15140122). The culture plate was
incubated in a 37°C and 5% CO2 incubator overnight. The sensor cartridge was hydrated
in the Seahorse XF calibrant in a in 37°C and non-CO2 incubator overnight (Aligent
Technologies, 100804-000) following the manufacturer’s guide. On the day of assay, 1
hour before the experiment, cells were washed with PBS and incubated in 180 µL/well
serum-free Seahorse XF DMEM (Aligent Technologies, 103575-100) which was
supplemented with 1 mM pyruvate (Aligent Technologies, 103578), 2 mM glutamine
(Aligent Technologies, 103579-100) and 10 mM glucose (Aligent Technologies, 103577100). The plate was placed in a 37°C and non-CO2 incubator for 1 hour prior to the assay.
Drug stock solutions from the XF Cell Mito Stress Test Kit (Aligent Technologies, 103016100) were prepared as the user guide described (100 µM Oligomycin, 100 µM FCCP, 50
µM Rotenone and Antimycin A). The drug solutions were loaded in to the corresponding
port s on the sensor cartridge, following the user guide, and the final concentration for
each well was 1.5 µM Oligomycin, 1 µM FCCP and 0.5 µM Rotenone and Antimycin A.
The OCR readings were determined and the OCR baseline reading before any drug
treatment was define as basal respiration. After oligomycin administration, the absolute
OCR reduction was defined as ATP-linked respiration. The absolute OCR reading after
FCCP administration was defined as maximal respiration, and the increase above
baseline after FCCP treatment was defined as spare capacity. The OCR reading after
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Rotenone & Antimycin A administration was defined as non-mitochondrial oxygen
consumption.

shRNA knockdown line generation
For tet-inducible shRNA cell lines, we used a lentivirus system and Lipofectamine 3000
(ThermoFisher Scientific, L3000008) to transfect 293FT cells using manufacturer’s
recommendations on virus production. Both shControl (Horizon, RHS4743) and shTrim24
(Horizon, RMM4431-200368247) were purchased through the functional genomic core at
University of Texas M.D. Anderson Cancer Center for cloning in a TRIPZ inducible
lentivirus vector. Next, lentivirus was collected from 293FT cells to transduce the TRIM24driven primary metaplastic carcinoma cell line 897. The shControl and shTRIM24-897
cells were grown under puromycin selection and sorted based on RFP after tetracycline
induction (1µg/ml).

RNA Library preparation and Deep-Sequencing
To perform deep sequencing of RNA (RNA-seq), total RNA was isolated from individual
tumors, in parallel with freshly isolated, disease free mammary glands (controls), using
Zymo Direct-zol RNA miniprep kit (R2050). RNA libraries were prepared using TrueSeq
RNA Library Prep Kit v1 (Illumina) followed by sequencing at the MD Anderson Next
Generation Sequencing Core Facility.

RNA-Sequencing Analysis
Sequences were first checked for quality using FASTQC and then adapters were trimmed
using Trimmomatic’s default settings [36]. Trimmed reads were checked again with
FastQC, and then aligned to the GRCm38 mouse genome assembly with the GENCODE
Release M14 transcriptome using the STAR aligner [37]. The reads were counted with
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HTSeq-Count [38] using the union mode to resolve multiple features. To determine the
gene expression profile between Control and TRIM24 overexpressing spheroids, a
differential expression analysis was performed to compare profiles of tumors with nontumor control using DESeq2 [39]. Genes were selected using a false discovery rate cutoff
of 5% and at least a fold change between groups. Hallmark pathways were calculated
using GSEA [40].

Gallios flow cytometry CellRox quantification
Spheroids embedded in Matrigel were collected according to the procedure described
above. Adherent cells were washed with PBS and trypsinized. Cell pellets were spin down
in the flow-cytometry tubes (Falcon, 352235). Cells were washed twice with 250 mM EDTA
diluted with PBS and passed through the strainers of the flow-cytometry tubes. Gallios
561 Flow Cytometer was used to quantify the percentage of cells with certain staining as
well as the signal intensities.

Total NADP(H) and NADP+/NADPH ratio Assays
Spheroids embedded in Matrigel were collected according to the procedure described
above. NADP+ and NADPH level was measure by Total NADP and NADPH Assay Kit
(Abcam, ab186033) and NADP/NADPH Assays kit (Abcam, ab65349) as the
manufacturer instructed. In brief, NADPH standard or NADP/NADPH reaction mixture
were reconstituted. NADPH standard solution was prepared with PBS to obtain 2 µM, 1
µM, 0.5 µM, 0.25 µM, 0.125 µM, 0.0625 µM, 0.0313 µM and 0 µM (blank control) serial
dilutions of NADPH standard. 50 µL/well cell lysate and NADPH standard dilutions were
added into a clear bottom 96-well microplate.

Then 50 µL/well total NADP(H) or

NADP/NADPH reaction mix was added into each well of NADPH standard and samples,
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incubated at room temperature for 1 hour. The absorbance was monitored at 460 nm with
the FLUOstar Omega plate reader.

NADPH Assays
Spheroids embedded in Matrigel were collected according to the procedure described
above. Reduced NADPH level was measure by colorimetric NADPH Assay Kit (Abcam,
ab186031) as the manufacturer instructed. Frist, NADPH standard and NADPH reaction
mixture were reconstituted. 100 µL NADPH stock solution was mixed with 400 µL PBS to
obtain 200 µM standard solution. Serial dilution was performed to obtain 100 µM, 50 µM,
25 µM, 12.5 µM, 6.25 µM, 3.13 µM and 0 µM (blank control) reduced NADPH standards.
50 µL/well cell lysate or NADPH standard dilutions were added into a clear bottom 96-well
microplate. Then 50 µL/well NADPH reaction mix was added into each well of NADPH
standard or samples, incubated at room temperature for 15 minutes. The absorbance was
monitored at 460 nm with the FLUOstar Omega plate reader. A standard curve was
constructed based on the readings of NADPH standard solutions and NADPH
concentration in each tested sample was calculated from the standard curve.

GSH/GSSG Ratio assays
GSH/GSSG-Glo Assay (Promega, V6611) was used to measure reduced glutathione and
oxidized glutathione as manufacturer instructed. 5 mM GSH was diluted to 320 µM with
water, 1:2 serial dilution was performed by adding 250 µL water to 250 µL GSH standards.
The final GSH standard concentration for each well in a 96-well plate ranged from 16 µM
to 0 µM (blank control). The tumorspheres in the 96-well plate was lysed with either 25 µL
total glutathione reagent (Luciferin-NT, 5X Passive Lysis Buffer, water) or oxidized
glutathione reagent (Luciferin-NT, NEM, 5X Passive Lysis Buffer, water) and the plate was
placed on a horizontal shaker at room temperature for 5 minutes. Luciferin Generation
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reagent (DTT, Glutathione-S-Transferases, and Glutathione Reaction Buffer) was
prepared according to the manufacturer’s recommendation and 50 µL was added to the
samples as well as the GSH standard dilutions. After 30 minutes of incubation at room
temperature, 100 µL Luciferin Detection Reagent was added to each well. After another
15-minute incubation at room temperature, luciferin signals were detected with the
FLUOstar Omega plate reader.

Statistical analysis
Statistical tests were performed using paired or unpaired Student’s t test, multiple t-test,
one-way or two-way ANOVA by the PRISM 8 software. Values with p <0.05 were
considered statistically significant.
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Results
The goal of this master thesis is to define how TRIM24 overexpression rewires
reduction-oxidation metabolism to promote survival and proliferation of cells derived from
a mouse model of metaplastic breast cancer. To study these aspects, all studies reported
here were conducted in vitro with three-dimensional spheroids.

TRIM24 drives EMT and stemness in mammary spheroids
To determine whether TRIM24 functions as an oncoprotein and drives
tumorigenesis in vivo, our lab developed a mouse model that conditionally over expresses
TRIM24 protein in mouse mammary epithelial cells to a level 2-3-fold greater than
observed in normal, age-matched mammary gland epithelial cells [33].
A piggyBac transposon vector was constructed with a human UBC promoter,
followed by loxP-lacZ-stop-loxP cassette, 5’ of the mTrim24 cDNA and a FLAG tag (pBacUbC-loxP-stop-loxP-Trim24-FLAG). After injection of the uncut construct along with
transposase RNA to the zygote pronuclei, transgenic Trim24 founder mice (Trim24LSL)
were identified by genotyping. To drive tissue-specific expression of transgenic mTrim24,
Trim24LSL mice were bred with MMTV-Cre recombinase mouse line (MMTV-CreTg/0) for
Cre recombinase-mediated excision of the floxed ß-Geo-stop codon. The resulting mice
conditionally overexpressed Trim24 in mammary epithelial cells, creating a mouse line
named Trim24COE (Figure 4). In this model, Trim24 over expression is sufficient for
initiation and progression of mammary carcinosarcoma. In order to generate a control line
for comparison to the Trim24COE line, MMTV-Cre virgin mice were aged in parallel, leading
to a rare spontaneous mammary tumor that lacked TRIM24 over expression [33].
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Figure 4: Generation of Trim24COE mouse line.
FVB stands for Friend Virus B, a stain used for transgenic injection; MMTV-Cre stands
for mouse mammary tumor virus long terminal repeat (LTR) promoter-Cre recombinase;
LoxP-ß-Geo-3xpA-LoxP, the floxed stop codon; UBC promoter, human ubiquitin C.
Trim24COE, the resulting mouse model that conditionally overexpressed TRIM24 in
mammary epithelial cells.
(Figure from Dr. Shiming Jiang)

From three different Trim24COE mouse mammary tumor-derived cell lines (mouse
tumor number 567, 64 and 897), I generated spheroid lines Trim24COE-567, Trim24COE-64,
and Trim24COE-897. Over expression of TRIM24 was confirmed by western blot (Figure 5).
Spheroids generated from an MMTV-Cre spontaneous tumor-derived cell line were used
as a control (MMTVCRE-823) with low level of TRIM24 expression, also confirmed by western
blot (Figure 5). TRIM24 over expression was also validated by Immunofluorescent staining,
along with cytokeratin 14 staining for the cytoplasm of basal epithelial cells (Figure 6). To
summarize, Trim24COE-567 and Trim24COE-64 spheroid expressed approximately 2-fold
increase of TRIM24, while Trim24COE-897 spheroid showed about 4-fold increase of TRIM24
compared to the TRIM24 level in MMTVCRE-823 spheroids.
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Figure 5: Over expression of TRIM24 in Trim24COE spheroids confirmed by western
blot.
A) Duplicates of each sample were load to run this western blot. 823 stands for MMTVCRE823

spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for

Trim24COE-897. B) Quantification of and statistical analysis of the TRIM24 western blot;
p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *.
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Figure 6: Over expression of TRIM24 in Trim24COE spheroids confirmed by IF
staining.
TRIM24 (green), cytokeratin 14 (K14, red), and DAPI-stained nuclei (blue) IF staining was
shown. Trim24COE spheroids showed brighter TRIM24 signals compared to the MMTVCRE823

spheroid; K14 (red) was stained to indicate the cytoplasm of basal epithelial cells and

showed similar IF signals across the MMTVCRE-823 spheroid and Trim24COE spheroids. 3D
images were reconstructed from 2D z-stacks images by Fiji (ImageJ package).

In recent years, multiple studies reported that normal-like mammary spheroids
display a cystic phenotype with a hollow center, while mammary spheroids derived from
tumor cells often exhibit a “grape-like” or completely discohesive phenotype [1][2][41][8].
Using bright-field microscopy, I observed a distinct difference in morphology between the
MMTVCre-823 control and Trim24COE spheroids on day 4 of culture (Figure 7). The MMTVCre823

control formed normal-cystic spheroids with a diameter less than 100 µm, while
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Trim24COE spheroids were larger in size, ranged from 150 µm to 200 µm. Dysregulated
cellular basal-apical polarity and planar polarity is a morphological feature of aggressive
tumors [42]. Basal-apical polarity separates the basal epithelial cells, which are associated
with adhesion and signaling, with the apical components; while planar polarity organizes
the cells across an epithelial cell sheet surface. Disruption of these cell polarity programs
contributes to cell migration and invasion in breast cancer [43]. Over expression of
TRIM24 leads to the formation of irregularly shaped spheroids with filopodia extending
into the surrounding Matrigel, which is a characteristic of disturbed planar polarity (Figure
7).
To further investigate the role of TRIM24 in this transformation, I created spheroids
from Trim24COE primary cells that were transduced with vectors bearing inducible shRNAs
that target Trim24 RNA for degradation and reduced expression (knockdown) of Trim24.
Using Trim24COE-64 and Trim24COE-897, doxycycline-inducible shTrim24 lines were
generated and named as shCT-64 (control) and shTrim24-64, shCT-897 (control) and
shTrim24-897. After 48 hours of 1 µg of doxycycline induction, western blots showed that
knockdown efficiency of shTrim24-64 was approximately 50% while shTrim24-897 has
about 40% knockdown according to the quantification from western blots (Figure 8A). The
knockdown of TRIM24 was also validated by IF staining – nuclear TRIM24 signal (green)
was visibly decreased in the two shTrim24 lines and cytokeratin 14 (red) staining the
cytoplasm of basal epithelial cells was unchanged (Figure 8B). The size of the spheroids
also dramatically decreased in shTrim24-64 and shTrim24-897 and invasive filopodia
were almost abolished upon TRIM24 knock down (Figure 7).
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Figure 7: Morphology of Trim24COE spheroids.
Brightfield images were taken on day 4 of spheroid culture with 20x magnification. (Scale
bar = 100 µm). MMTVCre-823 spheroids had circular shapes and their diameters were
around 70 to 80 µm. Trim24COE-567, Trim24COE-64 and Trim24COE-897 spheroids had irregular
and disorganized shapes and their long-axis diameters ranged from 150 µm to 200 µm.
Spheroid diameters decreased upon TRIM24 knockdown in shTrim24-64 and shTrim24897 compared to shCT-64 (control) and shCT-897 (control) respectively. Trim24COE-897
spheroids grew out invasive filopodia and knocking down TRIM24 in shTrim24-897
inhibited the formation of filopodia.
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A

B

Figure 8: Knock-down of TRIM24 in shTrim24-64 and shTrim24-897 spheroids
confirmed by western blots and IF staining.
A) All bands were normalized against a beta-actin loading control, then shTrim24 samples
were normalized against shCT samples to show the decreased fold change. (p<0.0001,
****; p<0.001, ***; p<0.01, **; p<0.05, *) B) TRIM24 (green), cytokeratin 14 (K8, red), and
DAPI-stained nuclei (blue) IF staining was shown; TRIM24 signals were greatly reduced
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in shTrim24-64 and shTrim24-897 compared to the staining in their controls. Cytokeratin
14 (K14, red) signal was not altered by TRIM24 knockdown. 3D images were
reconstructed with 2D z-stacks images by Fiji.

To quantify the spheroid size and invasive phenotype resulting from TRIM24 over
expression, I assessed the diameter and invasion percentage (invasion %) of the
Trim24COE spheroids with Fiji, an image processing package based on ImageJ software.
Twenty spheroids were randomly picked and long-axis spheroid diameters were
measured using the tool in the software. Trim24COE spheroids showed significantly higher
spheroid diameters compared to the MMTVCre-823 control. Knocking down TRIM24
decreased the spheroid diameters to < 100 µm in both shTrim24-64 and shTrim24-897
lines (Figure 9). To calculate invasion percentage, fifteen spheroids from each imaging
fields were randomly selected, and spheroids with distinctive filopodia were counted as
invasive spheroids. The total number of invasive spheroids were divided by the total
amount of all spheroids to get the invasive values for one imaging field. Ten different
imaging fields were used to get an average value of invasion% for each spheroid line. In
this way, we showed that three Trim24COE spheroids have much higher invasiveness
compared to the MMTVCre-823 control (Figure 10). Knocking down TRIM24 led to about 10%
decrease in the percentage of invasive spheroids in the shTrim24-897 compared to the
shCT-897 (Figure 10).
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Figure 9: Quantification of spheroid diameters showed TRIM24-dependent spheroid
size.
Twenty randomly selected spheroids in the MMTVCre-823 and three Trim24COE spheroid
lines were measured and quantification showed Trim24COE spheroids had significantly
larger diameters versus control. Knocking-down of TRIM24 decreased the spheroid
diameters in both shTrim24-64 and shTrim24-897 compared to their controls. (p<0.0001,
****; p<0.001, ***; p<0.01, **; p<0.05, *)

Figure 10: Quantification of spheroid invasion percentage showed TRIM24dependent invasiveness.
Fifteen spheroids from ten image fields were randomly selected and invasive spheroids
with filopodia were counted. The calculated invasion percentage showed 60% to 80% of
Trim24COE spheroids were invasive, while only around 10% of MMTVCre-823 spheroids are
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invasive. Knocking-down TRIM24 in shTrim24-897 decreased invasion percentage by
10%. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

EMT is a dynamic cellular process whereby epithelial cells lose signature
characteristics of cell-cell junctions, apical-basal polarity, and attachment to the basement
membrane and acquire more mesenchymal cell features, e.g. back-front polarity,
vimentin-based intermediate filaments [44]. Typical, although not always consistent, signs
of EMT include reduced expression of epithelial cell marker E-cadherin and increased
expression of mesenchymal cell marker N-cadherin [45]. In addition to gaining mobile
properties during EMT, cancer cells also enhance their resistance to anticancer drug and
oxidative stress, become able to escape senescence, and acquire self-renewal cancer
stem cell (CSC) characteristics [46]. During the formation of metastases, it’s believed that
cancer cells go through mesenchymal-to-epithelial transition (MET) to regain the epithelial
cell features and form the secondary tumor [44]. Some cancer cells do not reach complete
EMT,

but

retain

epithelial

cell

features

and

concurrently

express

both

epithelial/mesenchymal (E/M) phenotype [47]. This is termed as partial EMT and it is
recognized that partial EMT actually leads to higher metastatic potential than complete
EMT [47]. Intriguingly, I found in Trim24COE spheroids, both E-cadherin and N-cadherin
expression were largely reduced compared to control (Figure 11). Knocking down TRIM24
did not reverse the expression of E-cadherin or the expression of mesenchymal cell maker
N-cadherin (Figure 11).
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Figure 11: Western blots of EMT markers in Trim24COE spheroids
Duplicates of shCT and shTrim24 sample were load to run this western blot. 823 stands
for MMTVCRE-823 spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and
897 stands for Trim24COE-897. A) Both epithelial cell marker E-cadherin and mesenchymal
cell marker N-cadherin were downregulated in Trim24COE spheroids. B) Knock-down of
TRIM24 only decreased N-cadherin protein expression.

The EMT process is known to be regulated by transcriptional factors (EMT-TFs):
Snai1/2, Twist1/2, and Zeb1/2, which can lead to increased invasion and migration of
cancer cells [44, 48-51]. Therefore, I also assessed the expression of these typical EMTTFs in the Trim24COE spheroids and found that Snai1 and Twist1 were unchanged in
Trim24COE-567 but both were downregulated in Trim24COE-64 and Trim24COE-897 spheroids.
Zeb1, however, was dramatically upregulated in Trim24COE-567 and Trim24COE-64, but not in
Trim24COE-897(Figure 12). It has been reported that over expression of NRF2 prevents cells
undergo complete EMT and increased E-cadherin as well as ZEB-1 which shows a partial
EMT phenotype [52]. Here, Trim24COE spheroids did not express epithelial cell marker Ecadherin or mesenchymal cell marker N-cadherin, but exhibit increased expression of
Zeb1. It is possible that Trim24COE spheroids undergo partial EMT which could be a result
of over expression of NRF2. NRF2 over expression in the Trim24COE lines will be
elaborated in a later section.
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Figure 12: Different EMT transcription factor mRNA expression across Trim24COE
spheroid lines.
RT-qPCR data of Trim24COE spheroid was normalized with ribosomal gene 18s, then
normalized against MMTVCre-823. Three Trim24COE spheroid lines showed different mRNA
expression levels of typical EMT transcription factors. (p<0.0001, ****; p<0.001, ***;
p<0.01, **; p<0.05, *)

As an oncogenic transcription factor in breast cancers, c-MYC is known to promote
EMT, increase the proliferation of cancer stem-like cells and rewire metabolic pathways
that support the bioenergetic needs of proliferating cells [53-55]. c-MYC expression was
upregulated in Trim24COE-897 spheroids, and its expression was reduced upon TRIM24
knockdown (Figure 13).
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Figure 13: Western blots of c-MYC and their quantification showed TRIM24dependnet c-MYC at protein level.
Duplicates of each sample were load to run this western blot. 823 stands for MMTVCRE-823
spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for
Trim24COE-897. Quantification of western blot showed Trim24COE-897 had about two-fold
increase in c-MYC protein level compared to MMTVCRE-823; c-MYC protein level was
decreased upon TRIM24 knock down. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

In recent years, EMT has been linked to an increase in a self-renewing cancer
stem cell (CSC) population [49, 50]. In the context of breast cancer, breast cancer stem
cells (BCSCs) are rare cells that reportedly play a critical role in tumor initiation,
proliferation and metastasis. Kruppel-like factor 4 (KLF4), sex determining region Y-box 2
(SOX2) and cell-surface glycoprotein CD44 are typical cancer stem cell markers that are
highly expressed in cancer [56-58]. I found that CD44 and KLF4 expression were both
upregulated in Trim24COE-897 spheroids; SOX2 expression was particularly high in
Trim24COE-64 (Figure 14). Knock-down of TRIM24 decreased expression of CD44 and
SOX2 but not KLF4. which indicated that stemness characteristics of Trim24COE cells are
dependent on high levels of TRIM24 expression (Figure 14). Although driven by the same
oncoprotein TRIM24, the Trim24COE-567, Trim24COE-64 and Trim24COE-897 lines were
generated from three different endpoint mouse mammary tumors and showed different
degrees of TRIM24 over expression at the protein level (Figure 5). Based on the findings
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shown so far, three Trim24COE lines exhibited different levels of EMT marker and stemness
markers which indicates heterogeneity among the three spheroid lines.

Figure 14: Western blots and their quantification showed different BCSCs marker
levels in Trim24COE, shCT-897 and shTrim24-897 spheroids.
Duplicates of each sample were load to run this western blot. 823 stands for MMTVCRE-823
spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for
Trim24COE-897. Quantification of western blots showed high CD44 and KLF4 in Trim24COE897

; high SOX2 in Trim24COE-64 spheroids; and Trim24COE-567 showed only high CD44.

Knock-down of TRIM24 in shTrim24-897 decreased CD44 and SOX2 but not KLF at the
protein level. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

A major advantage of using three-dimensional spheroids is that they closely
recapitulate the normal or pathological in vivo mammary duct architecture. Unlike 2D cell
monolayers, the typical mammary 3D culture has multiple layers of cells that consist of
outer basal membrane, α6/β4 integrins, and tight junctions on the luminal side that express
ZO-1 [59]. This strictly defined basal-apical polarity is a key feature of the mammary gland
unit and loss of this feature is a critical event of tumor development [34, 59-62]. The
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literature shows that mammary organoids are arranged into two distinct layers, which are
basal epithelial cell layers that express cytokeratin-14 (K14), p63 and smooth muscle actin
(SMA) and luminal epithelial cells expressing cytokeratin-8 (K8) and progesterone
receptor (PR) [35]. To investigate if TRIM24 over expression affected the differentiation of
these cell compartments, I used IF staining and show that Trim24COE spheroids lacked a
luminal epithelial cell population but knocking down TRIM24 increased the expression of
luminal marker K8 on the inner layer of cells (Figure 15,16).

Figure 15: IF staining of K8 (luminal epithelial cell) and K14 (basal epithelial cell) in
Trim24COE spheroids.
Cytokeratin 8 (K8, green), cytokeratin 14 (K14, red), and DAPI-stained nuclei (blue) IF
staining showed MMTVCre-823 had strong K8 signal whereas Trim24COE spheroids had very
weak K8 signals; K14 signals were similar across the spheroid lines. 3D images were
reconstructed with 2D z-stacks images by Fiji.
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Figure 16: IF staining of K8 (luminal epithelial cell) and K14 (basal epithelial cell) in
Trim24COE, shCT-897 and shTrim24-897 spheroids.
Cytokeratin 8 (K8, green), cytokeratin 14 (K14, red), and DAPI-stained nuclei (blue) IF
staining showed that K8 signals recovered upon TRIM24 knockdown in shTrim24-64 and
shTrim24-897; K14 signals were not affected upon TRIM24 knock down. 3D images were
reconstructed with 2D z-stacks images by Fiji.

Immunoblots also showed that K8 expression was low in Trim24COE spheroids and
knocking down TRIM24 increased K8 expression (Figure 17). These results delineated
that TRIM24 over expression led to less differentiated mammary spheroids.

These

findings further support the results showing that TRIM24 over expression contributes to
increased stemness and decreased differentiation.
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Figure 17: Western blot of K8 (luminal epithelial cell) and K14 (basal epithelial cell)
in shCT-897 and shTrim24-897 spheroids.
Duplicates of each sample were load to run this western blot. 823 stands for MMTVCRE-823
spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for
Trim24COE-897. Quantification of western blots showed no cytokeratin 8 (K8) or cytokeratin
14 (K14) expression in Trim24COE spheroids; knocking down TRIM24 increased K8 but
decreased K14 at the protein level. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

Trim24COE-567, Trim24COE-64 and Trim24COE-897 spheroids were generated from cells
collected and cultured from endpoint mouse mammary tumors at the endpoint driven by
Trim24 over expression. Consistent with spheroid type-specific, differential expression of
EMT markers and stemness markers, their heterogeneity was further confirmed by RNAsequencing (Figure 18). Three Trim24COE spheroid lines exhibited an RNA expression
profile that was distinct from the MMTVCre-823 control. While within a broader Trim24COE
spheroid grouping, Trim24COE-567, Trim24COE-64 and Trim24COE-897 also showed distinct
clustering patterns (Figure 18). Between technical replicates, for example Trim24COE-897-1
and Trim24COE-897-2, the clustering pattern is consistent with each other, indicating good
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sample preparation. The heterogeneity among the three tumor-derived spheroid lines is
also apparent in their metabolic characteristics, which will be elaborated further in the
following sections.

Figure 18: RNA sequencing data revealed heterogeneity within the Trim24COE
spheroid groups
RNA-sequencing analysis done by Dr. Vrutant Shah; duplicates of each spheroid line were
used. Three Trim24COE spheroid lines exhibited clustering profiles that was distinct from
the MMTVCre-823 control; while Trim24COE-567, Trim24COE-64 and Trim24COE-897 showed
distinct clustering patterns compared with each other.

Highly invasive cancer cells have been reported to exhibit a stronger ability to
buffer reactive oxidative stress [9, 11, 14, 63-65]. Here, we used the CellRox reagent, a
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fluorogenic probe that measures intracellular ROS level in live cells. In an oxidative state,
CellRox emits strong fluorescent signals while in a reduced stated CellRox does not or
emit very weak fluorescence. We found that Trim24COE spheroids had lower ROS profiles
than the MMTVCRE-823 control (Figure 19). The shCT-64 and shCT-897 spheroid lines
showed similar ROS abundance, compared to their parental lines, while both shTrim2464 and shTrim24-897 exhibited much higher intracellular ROS compared to their knockdown controls (Figure 20).

Figure 19: CellROX staining showed low intracellular ROS in Trim24COE spheroids
compared to the MMTVCRE-823 control.
CellROX Deep Red (red), a reagent that detects intracellular ROS showed three
Trim24COE spheroid lines had lower CellROX signals compared to the control spheroid;
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DAPI nuclei (blue) staining was shown in blue; 3D images were reconstructed with 2D zstacks images by Fiji.

Figure 20: Low intracellular ROS levels in spheroids were dependent upon TRIM24
overexpression
CellROX Deep Red (red), and DAPI-stained nuclei (blue) staining was shown. Knocking
down TRIM24 increased the CellROX signals in shTrim24-64 and shTrim24-897
compared to their control. 3D images were reconstructed with 2D z-stacks images by Fiji.

H2O2, a major ROS entity generated from mitochondrial oxidative respiration, was
added to the spheroids to induce oxidative stress. After 24 hours of H2O2 treatment,
CellRox ROS staining showed increased intracellular ROS in MMTVCRE-823 spheroids,
while Trim24COE spheroids did not show significant changes in ROS level responding to
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H2O2 (Figure 21). In shTrim24-897, intracellular ROS was slightly induced upon H2O2
treatment compared to the shCT-897, which indicated that knocking down TRIM24
diminishes adaption to oxidative stress in this spheroid tumor-derived line (Figure 22).

Figure 21: Intracellular ROS increased in MMTVCre-823 spheroids after 24 hours of
H2O2 treatment but not in Trim24COE spheroids.
CellROX Deep Red (red), and CellROX combined with DAPI nucleus stain (blue) showed
increased CellROX signal in MMTVCre-823 spheroids after H2O2 treatment.
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Figure 22: Intracellular ROS increased in shTrim24-897 spheroids after 24 hours of
H2O2 treatment but not in shCT spheroids.
CellROX Deep Red (red), and CellROX combined with DAPI nucleus stain (blue) showed
increased CellROX signal in shTrim24-897 spheroids after H2O2 treatment; while
shTrim24-64 did not show increased CellROX signal after H2O2 treatment.

To further investigate whether lower cellular ROS, observed in Trim24COE
spheroids, is due to less mitochondrial activity or increased ROS scavenging, MitoSOX, a
reagent that specially enters mitochondria, was used to determine the mitochondrial ROS
level. Similar to CellROX signals, we found that Trim24COE spheroids exhibited lower
mitochondrial ROS levels (Figure 23). The MitoSox signals were not affected by 1 mM
H2O2 treatment for 24 hours. Mitochondrial ROS level plays an important role in
mitochondria-mediated cell death pathways [66]. Since addition of extracellular H2O2 did
not affect the ROS production in the mitochondria, the cell death triggered by 1 mM H2O2
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treatment for 24 hours was not mediated by mitochondria which will be elaborated in later
section.
The mitochondrial stress test by Seahorse is an assay to assess mitochondrial
function through measuring oxygen consumption rate (OCR) before and after drug
administration. In the beginning, before any drug treatment, basal OCR was recorded.
Then oligomycin was added to cells to block ATP synthase (complex V) of the electron
transport chain (ETC), followed by carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone
(FCCP) administration to break the mitochondrial membrane potential. Lastly Rotenone
and antimycin was added to inhibit complex I and complex III respectively which resulted
in shut down of mitochondrial respiration [67]. This assay revealed a lower basal
respiration, maximal respiration and ATP-linked respiration, as well as lower spare
capacity in Trim24COE-567 and Trim24COE-897 spheroids (Figure 24). Knocking-down TRIM24
in shTrim24-897 spheroids further decreased the mitochondrial capacity to respond to
stress which caused further decreased in basal respiration, maximal respiration, ATPlinked respiration, and spare capacity (Figure 24). Lower mitochondrial activity could
explain the lower mitochondrial and cellular ROS level in Trim24COE spheroids. Knocking
down TRIM24 increased cellular ROS but further decreased mitochondrial activity, which
indicated increased ROS upon TRIM24 knockdown was not contributed by mitochondria.

40

Figure 23: MitoSOX staining of mitochondrial ROS after 24 hours of H2O2 treatment
did not change in MMTVCre-823 or Trim24COE spheroids.
MitoSOX Orange (red), and MitoSOX combined with DAPI nucleus stain (blue) showed
unchanged MitoSOX signal in all spheroid lines after H2O2 treatment.
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Figure 24: Trim24COE spheroid showed decreased overall response to Seahorse Mito
Stress Test and TRIM24 knock down further decreased the response.
Basal respiration, the OCR reading before drug treatment; ATP-linked respiration, the
absolute OCR reduction after oligomycin administration; Maximal respiration, the absolute
OCR reading after FCCP administration; Spare capacity, the increase in OCR above
baseline after FCCP treatment. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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NADPH is an essential reducing equivalent that replenishes reduced glutathione
(GSH) in order for cells to combat oxidative stress. Due to increased ROS level results
from fast proliferation and oncogene signaling, proliferative cells are especially in greater
need of NADPH [8, 11, 68-71]. With a colorimetric total NADP(H) assay, we found that
total NADP+ and NADPH levels as well as the reduced NADPH level were significantly
higher in the Trim24COE spheroids (Figure 25). Upon TRIM24 knockdown, the total
NADP(H) levels showed a 5-fold decrease in shTrim24-64 and a 2-fold decrease in
shTrim24-897 versus parental controls. Reduced NADPH showed a 15% decrease upon
TRIM24 knock-down, suggesting that TRIM24 knockdown greatly decreased the NADP+
abundance instead of NADPH to cause a decrease in total NADP(H) (Figure 25).

Figure 25: Total NADP(H) and reduced NADPH levels were upregulated in Trim24COE
spheroids while decreased upon TRIM24 knock down.
NADP(H) and reduced NADPH abundance were determined using a total NADP(H) or
reduced NADPH standard curve, triplicates of samples were used. Trim24COE spheroids
showed about six to seven times higher total NADP(H) compared to the control. Trim24COE
spheroids showed about two-fold increase in reduced NADPH level. (p<0.0001, ****;
p<0.001, ***; p<0.01, **; p<0.05, *)
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TRIM24 over expression diverts glycolysis flux for more NADPH production
The most direct source of NADPH production in mammalian cell is the pentose
phosphate pathway (PPP), mediated by glucose-6-phosphate dehydrogenase (G6PD)
and 6-phosphogluconate dehydrogenase (PGD) [72, 73]. Additionally, quantitative flux
analysis showed that a comparable amount of NADPH production is also contributed by
serine-driven one-carbon metabolism [68]. In order to investigate the source of high
NADPH found in Trim24COE spheroids, spheroid samples were incubated with medium
with the desired isotope tracer for six hours before processing and metabolite abundance
was detected by liquid chromatography and mass spectrometry (LC/MS) (Figure 3A).
13

C6-glucose isotope tracing revealed that Trim24COE-897 spheroids divert the glycolysis flux

to the PPP shunt (Figure 26), and enzyme levels of G6PD and PGD were significantly
increased in Trim24COE-897 compared to the MMTVCRE-823 control and Trim24COE-567
spheroids (Figure 27A).

Figure 26:

13

C6-glucose isotope tracing revealed increased glycolysis diversion to

PPP shunt and 1C metabolism in Trim24COE-897 spheroids.

Metabolite abundance in PPP shunt (green square), and 1C-metabolism (pink square)
indicated increased glycolysis diversion to those pathways. (p<0.0001, ****; p<0.001, ***;
p<0.01, **; p<0.05, *)
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There was also an increase in the glucose-derived total 3PG/2PG abundance. 3phosphoglycerate (3PG) can be converted to serine through phosphoglycerate
dehydrogenase (PHGDH) and phosphoserine aminotransferase (PSAT1), fueling onecarbon metabolism to produce folate and NADPH [74-77]. In TRIM24COE spheroids, the
enzyme expression of PHGDH was also increased, as well as the downstream enzymes
SHMT1, SHMT2, MTHFD1 (Figure 27B). The expression of PGK, PHGDH, SHMT1/2 was
downregulated upon TRIM24 knockdown in shTrim24-897 spheroids, which indicated
TRIM24-dependent glycolysis diversion to one-carbon metabolism (Figure 27C).

A

B

C

Figure 27: Western blots of PPP and 1C metabolism pathway showed increased
enzyme levels in Trim24COE spheroids TRIM24-dependent enzyme levels in 1C
metabolism.
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Duplicates of each sample were load to run these western blots. 823 stands for MMTVCRE823

spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for

Trim24COE-897. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

Serine is one of the non-essential amino acids (NEAAs) that has received
increased attention in the field of cancer metabolism [77-79]. PHGDH, the first enzyme in
de novo serine synthesis, is amplified in some triple-negative-breast cancers [75]. Efforts
have been made to develop PHGDH-specific inhibitors to inhibit tumor growth. A selective
small-molecule inhibitor of PHGDH, CBR5884, was identified through screening 800,000
drug-like compounds [80]. After treating two lines of TRIM24COE spheroids with 60 µM of
CBR5884 for 24 hours, the TRIM24COE spheroids both showed approximately 30%
decrease in their viability (Figure 28) while not affecting the total NADP(H) level (Figure
28). TRIM24 knock-down sensitizes the spheroids to CBR5884: at 60 µM, shTrim24-897
line had more than 90% decrease in its viability (Figure 28). This decrease in viability could
be due to both less NADPH production and serine, glycine, and folate depletion. To
investigate the NADP(H) status, we performed total NADP(H) assays as well as NADPHonly assays. Total NADP(H) was increased in Trim24COE-567 and Trim24COE-897 compared
to the MMTVCRE-823 control after 24hr-CBR5884 treatment, while the NADPH level alone
was decreased in the two Trim24COE lines compared to the MMTVCRE-823 control (Figure
29). This indicated that NADPH was reduced and NADP+ was increased in both Trim24COE
lines in response to PHGDH inhibitors.
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Figure 28: CTG viability assays showed PHGDH inhibitor CBR5884 decreased
Trim24COE spheroid viability; the decrease in viability was enhanced upon TIRM24
knock down.
Triplicates were used for CellTitor-Glo viability assay. With 60 µM of CBR5884, both
Trim24COE-567 and Trim24COE-897 spheroid showed significant decrease in their viability;
viability of shTrim24-897 was greatly decreased upon 60 µM of CBR5884 treatment
compared to the control. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

Figure 29: Total NADP(H) and reduced NADPH assays revealed decreased reducedNADPH level in Trim24COE spheroids after treated with CBR5884.
Total NADP(H) and reduced NADPH were determined with a standard curve and CB839treated samples were normalized to DMSO-treated control samples. Triplicates were used.
(p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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To test if one-carbon metabolism precursors were essential for the survival of the
Trim24COE spheroids, we pre-treated the spheroids with CBR5884 for 24 hours then
assessed rescue of spheroid viability by supplying 500 µM 3PG in the culture media for
an additional 24 hours. 3PG supplement rescued the Trim24COE-567 and Trim24COE-897
spheroids and increased viability more than 60% (Figure 30). Although 3PG supplement
slightly rescued viability of shTrim24-897 spheroids, the effect of rescue was significantly
lower than that in shCT-897 spheroids. These results indicated that TRIM24 knockdown
lowers the flux of glycolysis to one-carbon metabolism, and inhibition of this diversion in
the context of TRIM24 knockdown cannot be rescued by 3PG supplement (Figure 30).

Figure 30: 3PG supplement rescued Trim24COE spheroids viability but failed to
rescue up TRIM24 knock down.
Viability of Trim24COE-567 and Trim24COE-897 spheroids pre-treated with CBR5884 was
increased after 3PG supplement. However, in shTrim24-64 and shTrim24-897, 3PG
addition failed to rescued the decrease in viability due to CBR5884 treatment.
(p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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TRIM24 over expression upregulated glutathione synthesis
Cancer cells often rely on high levels of glutamine and glutamate to fuel the TCA
cycle for ATP production, as well as de novo reduced glutathione (GSH) synthesis for
antioxidant defense [81-87]. With 15C5-glutamine tracing, we found that Trim24COE-567 and
Trim24COE-897 spheroids had a significantly higher abundance of glutamate and reduced
glutathione compared to the MMTVCRE-823 control, but not glutamine (Figure 31). This result
was further validated by a GSH/GSSG ratio assay which showed that TRIM24 over
expression induces de novo GSH synthesis from glutamate and increases the GSH/GSSG
ratio (Figure 31).

Figure 31: 15C5-glutamine tracing of Trim24COE spheroids and GSH/GSSG ratio assay
revealed increased reduced glutathione level in Trim24COE spheroids.
15

C5-glutamine tracing was performed with triplicate samples. 823-1/2/3 stands for

MMTVCRE-823 spheroid triplicate; 567-1/2/3 stands for Trim24COE-567; and 897-1/2/3 stands
for Trim24COE-897. Heatmap generated form the tracing data showed Trim24COE-567 and
Trim24COE-897 spheroids had a higher abundance of reduced glutathione, glutamate but not
glutamine compared to the MMTVCRE-823 control. Graph on the right showed the result of
GSH/GSSG ratio assay which validated the high GSH level in Trim24COE-897 spheroids.
(p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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We performed western blotting of enzymes in the GSH synthesis and recycling
pathways to assess the levels of enzymes involved in GSH synthesis (Figure 32). We
found that ASCT2 (SLC1A5), cystine-glutamate antiporter (SLC7A11) glutamine synthase
(GluL), glutaminase (GLS1), glutamate dehydrogenase (GluD) and glutathione synthase
(GSS) enzyme levels were significantly increased in Trim24COE-897 spheroids but not in
Trim24COE-567 spheroids (Figure 4D). The Glutathione reductase (GSR) level was also
upregulated in Trim24COE-897 to increase GSH recycling from GSSG. Glutathione
transferase (GST) and phosphorylated GST (GSTP) that were also significantly
upregulated in Trim24COE-897 but not Trim24COE-567 spheroids (Figure 32).

Figure 32: Western blot quantification of enzyme levels showed increased
glutaminolysis pathway and de novo GSH synthesis pathway in Trim24COE-897
spheroids.
Duplicates of each sample were load to run western blot. 823 stands for MMTVCRE-823
spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for
Trim24COE-897. Glutamine transporters (ASCT2, SLC7A11), glutaminolysis-related enzyme
(GLS1, ASNS), de novo GSH synthesis enzymes (GCLC, GSS) and GSH detoxification
enzymes (GST, GSTP), and NADPH-producing enzymes (IDH1, ME1) were upregulated
in Trim24COE-897 spheroids. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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Since the two Trim24COE spheroid lines were derived from two different endpoint
mouse mammary gland tumors driven by TRIM24 over expression, the two spheroid lines
exhibited heterogeneity and likely exploited different strategies to increase the cellular
GSH pool. Unlike Trim24COE-897, Trim24COE-567 spheroids showed a slight decrease in GSS
expression compared to the MMTVCRE-823 control. Trim24COE-567 spheroids also exhibited a
slight decrease in glutathione peroxidase 4 (GPX4) level, which suggested that Trim24COE567

spheroids decreased de novo glutathione synthesis while preserving the GSH pool.

Interestingly, both spheroid lines had upregulated asparagine synthase (ASNS) levels
compared to the control. ASNS also facilitates the conversion of glutamine to glutamate,
and it has been reported to increase the expression of GluL to sustain de novo GSH
synthesis [88].
In shTrim24-897 spheroids, enzyme expression of ASCT2, GluL, GLS1, GPX4,
GSS, and GST, as well as ASNS, were all downregulated upon TRIM24 knockdown
(Figure 33). This result illustrated that TRIM24 over expression drives the upregulation of
de novo GHS synthesis from glutamate in Trim24COE -897 spheroids.
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Figure 33: Western blot quantification showed downregulated enzymes in
glutamate metabolism pathway and de novo GSH synthesis pathway in shTrim24897 spheroids
Glutamine transporters (ASCT2), glutaminolysis-related enzyme (GLS1, ASNS), de novo
GSH synthesis enzymes (GSS) and GSH detoxification enzymes (GST), and NADPHproducing enzymes (IDH1, ME1) were downregulated upon TRIM24 knock down.
(p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

A previous study showed that GLS1, the critical enzyme that converts glutamine
to glutamate, is essential for progression of TNBC [89]. CB-389 is a small molecule
inhibitor that targets GLS1 specifically (Figure 34), and it showed antiproliferative effects
against a panel of TNBC cell lines grown in 2D [90]. CB839 is a potent glutaminase
inhibitor that depletes the substrate for de novo GSH synthesis and thus increases
intracellular ROS [91].
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Figure 34: GLS inhibitor CB839 inhibits the conversion of glutamine to glutamate.
CB839 is an allosteric inhibitor specifically for GLS1. Upon glutaminase inhibition, CB839
depleted the substrate for de novo GSH synthesis.

We found the intracellular and mitochondrial ROS levels were increased in
Trim24COE spheroids after treating with 10 µM CB-839 for 48 hours (Figure 35). Trim24COE567

showed a slight decrease in its viability while Trim24COE-897 spheroids showed a 30%

decrease in response to CB-839 treatment (Figure 36). When the drug was combined with
TRIM24 knockdown, spheroid viability showed an approximately 50% decrease in the
shTrim24-897 line (Figure 36). TRIM24 over expression led to increased levels of GLS1,
and it is possible that Trim24COE spheroids develop addiction to GLS1 downstream
metabolite glutamate. TRIM24 knockdown decreased the GLS1 expression, thus
sensitizing the cells to further pharmacological inhibition of GLS1 by CB839.
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Figure 35: CB839 treatment for 48 hours increased intracellular and mitochondrial
ROS levels in Trim24COE spheroids.
Both MitoSOX Orange (upper panel) and CellROX Orange (lower panel) signals were
increased in Trim24COE-567 spheroids and Trim24COE-897 spheroids upon GLS1 inhibitor
CB839 treatment.
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Figure 36: Viability of Trim24COE spheroids was decreased after 48-hours CB839
treatment; the drug effect was enhanced by TRIM24 knock down.
CTG luminescence was measured and CB839-treated samples were normalized against
DMSO-treated control samples. Triplicates were used for CellTitor-Glo viability assay.
With 10 µM of CB839, both Trim24COE-567 and Trim24COE-897 spheroid showed significant
decrease in their viability; viability of shTrim24-897 was greatly decreased upon CB839
treatment compared to the control. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

To investigate how CB-839 affects the NADP(H) pool and NADP+/NADPH ratio,
we performed a total NADPH assay and NADP+/NADPH ratio assay. The results revealed
that the total NADPH level is decreased in the Trim24COE-567 spheroids as well as the
NADP+/NADPH ratio. Total NADPH levels were increased in control and Trim24COE -897
spheroids and the increase was contributed by upregulated NADP+ responding to GLS1
inhibition (Figure 37). The increased level of NADP+ was likely a result of increased GSH
recycling by GSR in Trim24COE-897 spheroids. In shTrim24-897, GLS1 inhibitors CB-839
decreased the total NADP(H) level compared to the shCT-897 control.
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Figure 37: Total NADP(H) and NADP+/NADPH ratio assay of Trim24COE spheroids,
showed increased NADP+ abundance after CB839 treatment.
Total NADP(H) and reduced NADPH were determined with a standard curve and CB839treated samples were normalized to DMSO-treated control samples. Triplicates were used
for both assays. The total NADPH level increased after treated with CB839 in both
MMTVCre-823 and Trim24COE-897 spheroids. In NADP/NADPH ratio assay, Trim24COE-897
spheroids had significantly higher NADP/NADPH ratio than MMTVCre-823 which indicated
uppregulated GSH recycling to replenish GSH pool after GLS inhibition.
(p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

A more straightforward way to inhibit de novo GHS synthesis is by using an
irreversible inhibitor of GCL, such as Buthionine sulfoximine (BSO) [92]. By targeting the
enzyme that catalyzes the first and rate-limiting step of de novo GSH synthesis (Figure
34), BSO was reported to promote ROS accumulation and induce apoptotic cell death [93],
as well as ferroptosis in a panel of established cancer cell lines grown as 2D-cultures [92].
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In the context of TRIM24 over expression, 24-hour treatment of BSO was not effective in
reducing spheroid viability (Figure 38). In shTrim24-897 spheroids, viability was
significantly decreased with 20 µM to 200 µM BSO treatment for 24hrs, compared to shCT897. TRIM24 knockdown sensitizes the cells to BSO treatment and induces more cell
death compared to the shCT-897. The total NADPH level was not altered by BSO
treatment in either Trim24COE -897 or shTrim24-897 spheroids (Figure 39).

Figure 38: CTG viability assay showed BSO treatment had additive effect with
TRIM24 knock down.
CTG luminescence was measured and BSO-treated samples were normalized against
DMSO-treated control samples. BSO alone did not affect the viability of Trim24COE
spheroids; however, spheroid viability drastically decreased upon TRIM24 knock down.
(p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

57

Figure 39: Total NADP(H) levels were increased in Trim24COE-567 and Trim24COE-64
spheroids but not Trim24COE-897 spheroids.
Total NADP(H) levels were determined relative to a standard curve and BSO-treated
samples were normalized to DMSO-treated control samples. Triplicates were used for
both assays. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

Since CB-839 and BSO both inhibit the GSH synthesis pathway, combining them
with a GLS inhibitor upstream of a GCL inhibitor that directly targets the enzyme may
enhance inhibitory effects on the viability of Trim24COE spheroids. A significant decrease
in viability was observed in all three Trim24COE lines, as well as the MMTVCRE-823 control,
with the combined treatment, compared to BSO treatment alone (Figure 40). In the context
of TRIM24 knockdown, combined treatment did not exhibit a greater effect than CB-839
alone or BSO alone in shCT-897 or shTrim24-897 spheroids. With combined drug
treatment, the shTrim24-897 line also showed significantly decreased viability comparing
to the shCT-897 line which meant TRIM24 knockdown sensitized the spheroids to the
combined drug treatment (Figure 40).
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Figure 40: CTG viability assay showed different responses to combined GSH
synthesis inhibitor treatment in Trim24COE spheroids, shCT-897 and shTrim24-897.
CTG luminescence was measured and CB839 and BSO-treated samples were normalized
against DMSO-treated control samples, triplicates were used. CB839 and BSO combined
treatment showed greater effect than these drugs alone in Trim24COE-567. Combined
treatment did not work in shCT or shTrim24 spheroids. (p<0.0001, ****; p<0.001, ***;
p<0.01, **; p<0.05, *)
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TRIM24 over expression upregulates reducing power through increased
NRF2 activity
The Keap1-NRF2 pathway is the master regulator of cytoprotective defense under
oxidative stress. Under normal physiological conditions, Kelch-like ECH-associated
protein 1 (KEAP1) binds to nuclear factor erythroid2-related factor (NRF2) and promotes
NRF2 degradation by Cullin 3 (CUL3) mediated-polyubiquitination [94, 95]. When ROS
levels increase, KEAP1 oxidation leads to a conformational change of KEAP1, leading to
release of NRF2. NRF2 then enters the nucleus, binds Maf and initiates transcription via
interaction with antioxidant response elements (AREs) of target genes, such as Nox1, Gcl,
and Gst [95]. This is a cytoprotective response to maintain homeostasis, oppose cellular
damage and suppress tumor promotion. During tumorigenesis, DNA damage
accumulates and leads to constitutive NRF2 nuclear translocation. NRF2-activated
transcription of ARE element-regulated genes increases expression of G6PD, PGD,
TALDO1, MTHFD2, GCL, GSS, GSR and ME1 to enhance cryoprotection [86]. This
provides advantages for cancer cells to endure high endogenous ROS and escape ROSinduced apoptosis. Therefore, NRF2 hyperactivity favors cancer cell survival, which can
lead to resistance to chemotherapy [96-98]. Subsequent metabolic pathways regulated by
NRF2 (GSH synthesis and recycling, NADPH regulation, antioxidant detoxification) will
also enhance antioxidant defenses and promote cellular proliferation [8].
Extracellular H2O2 addition is known to promote NFR2 translocation to the nucleus
and activate ARE element-regulated transcription [99] [100]. To investigate if survival of
Trim24COE spheroids under ROS stress depends on NRF2 activation, we first treated the
spheroids with extracellular H2O2 and found TRIM24 over expression increased resistance
to H2O2. After 24-hours of 1 mM H2O2 treatment, cell viability of control MMTVCre-823
spheroids was drastically decreased (Figure 41). In contrast, the viability of Trim24COE -567
spheroids was not affected; and there was only about a 30% decrease of viability in the
Trim24COE-897 spheroids. When the dose of H2O2 was increased to 2mM, both MMTVCre-823
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and Trim24COE-897 spheroids exhibited very low or zero viability, while Trim24COE -567 was
still resistant to the high dose oxidative stress. In both shTrim24-64 and shTrim24-897,
after 24 hours of 1 mM and 2 mM H2O2 treatment, cell viability was significantly decreased
compared to their sh-Controls (Figure 41). This finding indicates that TRIM24-knockdown
sensitizes the cells to reactive oxygen species H2O2.

Figure 41: CTG viability assay showed resistance to H2O2 was TRIM24 dependent.
CTG luminescence was measured and H2O2 samples were normalized against DMSOtreated control samples. After 24-hours of 1mM H2O2 treatment, spheroids with high
TRIM24 levels (Trim24COE, shCT spheroids) showed resistance to H2O2 treatment while
spheroids with relatively lower TRIM24 levels (MMTVCre-823, shTrim24 spheroids) showed
significant decreased in viability upon 1mM H2O2 treatment. (p<0.0001, ****; p<0.001, ***;
p<0.01, **; p<0.05, *)

After 24 hours of 1 mM H2O2 treatment, the total NADP(H) level was not
significantly altered in the Trim24COE spheroids. However, the reduced NADPH abundance
in Trim24COE

-897

spheroids was significantly decreased in response to 1 mM H2O2,

indicating more NADPH was converted to NADP+ by the spheroids to buffer oxidative
stress (Figure 42). The shCT-897 line showed a moderate increase in total NADP(H) level
while the shTrim24-897 spheroids failed to increase total NADP(H) level in response to
H2O2. Similar to its parental line, shCT-897 spheroids had a decrease in reduced NADPH
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abundance after 500 µM and 1 mM H2O2 treatment, and knocking down TRIM24 impairs
the ability to utilize NADPH (Figure 42). Together, this result indicated that knocking down
TRIM24 impaired the spheroids’ adaptation to oxidative stress, failed to increase the total
NADP(H) pool and utilize reduced NADPH as a part of an antioxidant defense in shTrim24897.

Figure 42: Usage of reduced NADPH in response to H2O2 treatment was impaired by
TRIM24 knock down.
Total NADP(H) and reduced NADPH were determined with a standard curve and 1 mM
H2O2 -treated samples were normalized to non-treated control samples. CT stands for nontreated negative control samples. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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In previous results, we showed that Trim24COE spheroids increase antioxidant
defense by upregulating NADP(H) production and de novo synthesis of GSH. Since
Trim24COE spheroids exhibited high resistance to H2O2, which also activates an NRF2mediated antioxidant response, I hypothesized that NRF2 is potential mediator between
TRIM24 over expression and the upregulation of downstream pathways. We first
assessed mRNA levels of Nrf2 and its known target genes by qRT-PCR. In the non-treated
condition, Trim24COE-897 spheroids had an approximately two-fold increase in Me1, Phgdh,
Mthfd2, Nampt, and Gclc expression, compared to the MMTVCre-823 control (Figure 43). Of
note, in spite of an upregulated TRIM24 protein level, Trim24 mRNA was not
overexpressed, compared to control levels, in Trim24COE-567 or Trim24COE-897 at this time
point (day 4 of spheroid culture). After 24hrs 1mM H2O2 treatment, both Trim24COE lines
showed drastically increased Nrf2 expression. Trim24COE-567 also had significantly
increased expression of NADPH dehydrogenase (Nqo1); Pgd in the PPP shunt; Me1 in
the TCA cycle; Shmt1, Shmt2, Mthfd2 in the one-carbon metabolism; Slc7A11, Asns, Gclc,
Gclm, Gss, Gpx4, and Gspt in the GSH synthesis and detoxification pathway. While
slightly different from the response of Trim24COE-567 to H2O2, Trim24COE-897 had upregulated
expression of G6pd and Pgd in the PPP pathway; Slc7a11, Asns, Gclm, Gpx4, and Gsr in
the GSH synthesis and recycling pathway (Figure 43). The increase in Nrf2 as well as
Nrf2-targeted gene expression likely underpins the resistance to H2O2 treatment in
Trim24COE spheroids.
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Figure 43: Nrf2 and its target genes mRNA expression in Trim24COE spheroids was
induced by 24-hour 1mM H2O2 treatment.
qRT-PCR data of non-treated Trim24COE spheroids were normalized with ribosomal gene
18S, then normalized against MMTVCre-823. H2O2-treated samples were first normalized
with 18S then normalized against non-treated control samples. After 1mM H2O2 treatment,
Nrf2-target genes in 1C metabolism, glutaminolysis and GSH synthesis pathway were
significantly increased. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

The expression of these genes is also Trim24-dependent— knocking down Trim24
in shTrim24-897 spheroids resulted in a more than 50% decrease in Nrf2 and NRF2
targeted gene expression in the PPP shunt and one-carbon metabolism, as well as the
GSH synthesis pathway (Figure 44). Trim24 and Nrf2 expression was induced by 500 mM
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and 1mM H2O2 treatment in shTrim24-897 spheroids. With high expression of Nrf2 in
response to H2O2, target genes in the downstream NADPH and GSH producing pathways
were all upregulated in response (Figure 44).

Figure 44: Nrf2 and its target gene mRNA expression was decreased upon Trim24
knock down but induced after 24-hour 1mM H2O2 treatment in shTrim24-897.
qRT-PCR data of non-treated shCT-897 and shTrim24-897 spheroids were normalized
with house-keeping gene 18S, then normalized against shCT-897. H2O2-treated samples
were first normalized with 18S then normalized against non-treated control samples. Upon
Trim24 knock down, Nrf2-target genes in 1C metabolism, glutaminolysis and GSH
synthesis pathway were significantly decreased compared to the shCT-897. Nrf2-target
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gene expression was induced in shTrim24-897 compared to the shCT-897 after 1mM
H2O2 treatment. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

To complement RNA assessments, I determined NRF2 protein levels. Trim24COE567

and Trim24COE-897 exhibited increased expression of NRF2 protein level compared to

MMTVCRE-823 while knocking down TRIM24 decreased NRF2 expression in shTrim24-897
(Figure 44). After treatment with 1 mM of H2O2, NRF2 protein levels as well as GSL1,
GCLC, PHGDH were slightly upregulated in Trim24COE-897 (Figure 45). With 500 µM and 1
mM of H2O2 for 24 hours, shCT-897 responded with a significantly higher NRF2 expression
while shTrim24-897 failed to increase the NRF2 level (Figure 47). In contrast to the Trim24
mRNA level, H2O2 treatment for 24 hours did not affect the TRIM24 protein levels in shCT
or shTrim24-897 lines. PHGDH, the enzyme that leads glycolysis metabolite 3PG to onecarbon metabolism, was also upregulated by H2O2 in shCT-897. PHGDH protein level was
increased in shTrim24-897, as well, but still significantly lower compared to shCT-897.
Similarly, GCLC and GLS1 also failed to increase in response to H2O2 upon TRIM24
knockdown. Taken together, TRIM24 regulates Nrf2 expression, NRF2 protein level as
well NRF2 downstream enzyme levels; knocking down TRIM24 results in downregulated
NRF2 level as well as NRF2 target enzyme levels.
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Figure 45: Western blots and their quantification of NRF2 showed TRIM24dependent NRF2 protein level.
Duplicates of each sample were load to run this western blot. 823 stands for MMTVCRE-823
spheroid; 567 stands for Trim24COE-567; 64 stands for Trim24COE-64; and 897 stands for
Trim24COE-897. (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

Figure 46: Western blot quantification showed NRF2 downstream pathway enzyme
levels were increased in Trim24COE spheroids after 24-hour 1mM H2O2.
H2O2-treated samples were first normalized with beta-actin then normalized against nontreated control samples (CT). (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)
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Figure 47: Western blot quantification showed NRF2 downstream pathway enzyme
levels were downregulated in shTrim24-897 spheroids compared to shCT-897 after
24-hour 1mM H2O2.
H2O2-treated samples were first normalized with beta-actin then normalized against nontreated control samples (CT). (p<0.0001, ****; p<0.001, ***; p<0.01, **; p<0.05, *)

68

Discussion
ROS is a double-edged sword in cancer biology, acting in both tumor suppression
and tumor progression. It has been widely reported that intracellular and extracellular ROS
promote cell proliferation and migration [101-104]. Administration of mitochondrial ROS
scavengers to lower ROS level has been shown to block lung metastasis from MDAMB231 human breast cancer cells [105]. In contrast, increasing ROS level is also an
anticancer response to ionizing radiation and chemotherapy [106, 107].
The dynamic and complex interplay between ROS abundance and cancer is
primarily based on the delicate balance between ROS production and scavenging. ROS
generation, signaling and regulation are highly orchestrated processes which are rewired
in cancer cells to benefit proliferation, invasion and epigenetic alterations that lead to
tumor progression [14]. Numerous studies show that cancer cells exhibit persistently high
ROS level due to their rapid growth, limited nutrients and oxygen availability, as well as
stimuli from the tumor microenvironment [104, 108-110] . To compensate oxidative stress,
cancer cells develop higher antioxidant capacity than their normal counterparts to
preserve essential biological functions. Here in this study, we present that TRIM24 over
expression upregulates antioxidant defenses through NRF2; knocking down TRIM24
downregulates Nrf2 expression and dampens cellular adaption to oxidative stress, thus
further sensitizing spheroids to metabolic inhibitors that target NAPHD or GSH production.
Breast cancer cells bear higher ROS level compared to non-transformed cells, due
to mitochondrial dysfunction [111]. Mitochondrial activities were indeed impaired in
Trim24COE spheroids compared to the MMTVCre control; however, MitoSox staining
showed that mitochondrial ROS levels were lower instead of higher in Trim24COE
spheroids. A recent study comparing redox balance across BC cell lines showed that
extracellular H2O2 treatment only increased ROS in the nontransformed MCF10A cell line;
whereas, TNBC cell lines (BT549, MDA-MB-486 and MDA-MB-231) exhibited a greater
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capacity to balance oxidative stress [112]. In accordance with this published work,
Trim24COE spheroids also showed resistance to high-dose H2O2 treatment. However, in
contrast to 2D-cultured TNBC cell lines, baseline ROS levels in Trim24COE spheroids were
lower than the MMTVCre control which indicated a lower oxidant status. CellRox staining
revealed that 24 hours of H2O2 treatment visibly increased ROS levels in MMTVCre control
but not in Trim24COE spheroids, which remained low. Knocking down TRIM24 in shTrim24897 spheroids increases the intracellular ROS level, which suggests TRIM24-dependent
ROS scavenging.
Glycolysis was the first metabolic pathway studied in cancer and lactate
dehydrogenase-A (LDH-A) was the first enzyme identified as a target of oncogene c-Myc
[113]. Since then, extensive investigations found that aerobic glycolysis in cancer cells
results from aberrant activation of oncogenes Kras, c-Myc and the PI3K-Akt-mTOR
pathway [53, 114-116]. Other than a bioenergetic effect, a major advantage of high-rate
glycolysis is an increased availability of anabolic pathway precursors [12]. Previous work
in our lab and by others have shown that TRIM24 exploits glucose metabolism to promote
malignant transformation [32, 117]. Trim24COE spheroids exhibited high glycolysis flux and
an especially high abundance of 3PG/2PG, indicating increased diversion from glycolysis
to 1C metabolism. It has been reported that the 1C pathway is particularly upregulated in
MDA-MB231 metastatic subclones [118]. The expression of mitochondrial 1C pathway
enzymes SHMT2 and MTHFD is also induced in breast cancer [77, 119]. Trim24COE-897 but
not Trim24COE-567 spheroids had significantly upregulated 1C metabolism enzymes
SHMT1/2 and MTHFD1; the diversion from glycolysis to the 1C pathway is also dependent
on TRIM24 over expression in Trim24COE-897. Inhibition of this diversion decreased the
viability of Trim24COE and subsequently decreased the NADPH level; knocking-down
TRIM24 induces cell death and cannot be rescued by 3PG supplement.
Glutamate synthesis was upregulated in both Trim24COE lines while de novo
glutathione synthesis was only regulated in Trim24COE-897 spheroids. This indicated the
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divergent utilization of glutamate in the two Trim24COE lines, the high abundance of
glutamate in Trim24COE-567 spheroids might be used for non-essential amino acid synthesis
other than generating GSH [120]. Inhibition of glutaminolysis with CB839, but not direct
inhibition of GSH synthesis with BSO, induced cell death in both Trim24COE lines. Reduced
GSH consequently pushed the cells to compensate with increased GSH recycling, thus
increasing the NADP+/NADPH ratio in Trim24COE-897.

Interestingly, knocking-down

TRIM24 sensitized the spheroids to both CB839 and BSO. Combining the two drugs with
TRIM24-knockdown had an additive effect in reducing cell viability.
NRF2 has been report to exert both tumor suppressive and tumor promoting
characteristics [121]. Under normal conditions, NRF2 activation is initiated by disrupted
interactions with its binding partner KEAP1. It’s well-established that NRF2 protein is
aberrantly accumulated in many different types of cancers [98, 121, 122]. In cancer cells,
Nrf2 transcription can be activated independently of KEAP1, induced by oncogene Kras,
Braf and Myc to promote tumorigenesis and protect them from oxidative stress [97].
Trim24COE-897 spheroids showed more than two-fold increase in c-Myc protein level. Since
oncogenic Myc is known to augment the transcription of Nrf2 [97], upregulated c-MYC
could be a potential mediator between TRIM24 over expression and high NRF2 level in
Trim24COE-897 spheroids. There is also a growing amount of evidence that crosstalk
between NRF2 and tumor suppressor p53 impacts the capacity to mitigate oxidative stress.
A p53 target gene p21 (CDKN1A) has been shown to interfere with NRF2 degradation by
binding KEAP1, thus stabilizing NRF2 [123]. Other researchers reported that p53
counteracts the NRF2-mediated transcription of ARE element-containing genes through
direct inhibition of these promoters [124]. In 3D spheroid culture, NRF2-p53 coregulation
depends on context, as NRF2 signaling is reportedly independent of p53 in invasive TNBC
spheroids [125].
Using ChIP-qPCR, Zhang et al. discovered that NRF2 regulates transcription of
TRIM24. The phosphorylation of NRF2 is promoted by bone morphogenic protein 8A
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(BMP8A), a member of transforming growth factor β (TGFβ), to enhance survival and
resistance to drug [126]. Here, we showed that NRF2 is induced by TRIM24 over
expression. Through activating the transcription of ARE element-regulated genes, NRF2
plays a crucial role in activating enzymes that increase cytosolic NADPH production [94].
With high NRF2 protein levels in Trim24COE spheroids, the total NADP(H) and reduced
NADPH abundance are also much greater, compared to controls. Inspired by the
resistance of Trim24COE lines to high-dose H2O2 treatment, we found that NRF2 and its
known downstream target genes in the antioxidant program [86, 127] were upregulated in
Trim24COE-897 lines and downregulated upon TRIM24 knock-down. Under oxidative stress,
created by extracellular H2O2 addition, Nrf2 mRNA expression was induced in both
Trim24COE lines and shTrim24-897 lines. However, the NRF2 protein level was only
induced in Trim24COE-897 but downregulated in shTrim24-897. Knocking-down TRIM24
under oxidative stress abolished the increase of NRF2 protein but not the mRNA. It’s
possible that TRIM24 interferes with the NRF2 protein degradation process to increase
the NRF2 level, instead of directly promoting Nrf2 transcription. It would be interesting to
learn if KEAP1 protein level is regulated by TRIM24 under oxidative stress in future studies.
Breast cancer is a highly heterogeneous disease, and several studies in recent
years attempted to elucidate heterogenous metabolic preferences or dependencies
across BC subtypes. A recent single-cell RNA sequencing (scRNA-seq)-based, multiomics study corroborated lineage-specific metabolic heterogeneity in mammary epithelial
cells (MECs) [128]. This study highlighted that enrichment in glycolysis-related pathways
occurred in basal epithelial cells and enriched oxidative respiration was present in luminal
epithelial cells which indicates higher mitochondrial activity. Bioinformatics analysis further
demonstrated that breast cancer cells retain the metabolic features of their cellular origin,
for instance, a subgroup of TNBC cells that derived from the luminal progenitor cells
display high oxidative respiration which is the same as their cell of origin [128]. TNBC can
also be classified as metabolic-pathway-based subtypes (MPSs) and each subtype has
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distinct molecular subtype distributions and genomic alterations [129]. With a multi-omics
database of 465 TNBC patient samples, Gong et al. identified three MPSs: MPS1 with
upregulated lipid metabolism; MPS2 with upregulated carbohydrate and nucleotide
metabolism; and MPS3 with partial pathway dysregulation [129]. Given the metabolic
heterogeneity of breast cancer, it is important to understand the mechanistic basis for
variation in redox status between different breast cancer subtypes.
Trim24COE-567 and Trim24COE-897 lines are both derived from mouse mammary
tumors driven by Trim24 over expression. However, the primary cell lines were generated
from endpoint tumors, which have distinct gene expression patterns as confirmed by RNA
sequencing. Although all Trim24COE spheroid lines have a better capacity to handle
oxidative stress, they may have rewired metabolic pathways in their own distinct way to
achieve antioxidant defense, due to heterogeneity (Tables 1, 2 and 3). Trim24COE-897
spheroids

upregulated

the

PPP

shunt,

1C-metabolism,

glutamate

synthesis,

glutaminolysis, GSH synthesis, and NRF2 levels to enhance the production of reducing
equivalents and GSH. On the other hand, Trim24COE-567 spheroids only increased 1Cmetabolism and glutamate synthesis. As Trim24COE-567 spheroids showed remarkable
increases in proline abundance, compared to the control and Trim24COE-897, it’s possible
that Trim24COE-567 spheroids are using proline anabolism/catabolism pathways to diminish
the deleterious effect of ROS [130, 131]. This is an avenue of potential future
determinations.
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Table 1: Summary of rewired glycolysis and 1C-metabolism in Trim24COE
spheroids and shCT/shTrim24-897 spheroids

Table 2: Summary of rewired GSH synthesis pathway in Trim24COE
spheroids and shCT/shTrim24-897 spheroids
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Table 3: Summary of NRF2-regulated response under oxidative stress in
Trim24COE spheroids and shCT/shTrim24-897 spheroids

In conclusion, TRIM24-overexpressing mammary tumor spheroids have less
intracellular ROS level compared to the MMTVCre control breast cancer spheroids. The
low ROS level is the result of low mitochondrial ROS production, as well as increased
NADPH and GSH production driven by TRIM24 over expression. The upregulated
reducing power and antioxidant pathways inTrim24COE spheroids promote cell survival
under oxidative-stress conditions. NRF2, as a transcription target of TRIM24, acts as a
central mediator between TRIM24 over expression and downstream metabolic
reprogramming. Metabolic heterogeneity exists between TRIM24-overexpressing
spheroid lines. Although mammary tumorigenesis was driven by the same oncoprotein,
Trim24COE-567 and Trim24COE-897 spheroids exhibited different degrees of TRIM24 over
expression and, likely, took different routes to achieve higher antioxidant defense to
combat oxidative stress. As tumors respond differently to specific inhibitors, metabolic
heterogeneity needs to be taken into account when designing potential therapeutic plans.
Knocking-down or inhibiting TRIM24 in combination with metabolic inhibitors may offer a
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promising direction in treating MpBC tumors, which requires considerable preclinical
assessments and further investigations to determine.
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Appendix
Appendix 1: List of antibodies used for immunoblots
Antibody
Trim24
beta-actin
SMA
PGK
PGM1
Enolase1
PCK1
GLS
HIF1-a
ASNS
Cytokeratin 5
cytokeratin14

species
Rb
Ms
Rb
Rb
Rb
Rb
Rb
Rb
Ms
Rb
Rb
Ma

MW
130 KD
42 KD
42 KD
45 KD
61 KD
47 KD
69 KD
58,65kD
93 KD
64 KD
62 KD
40, 68 KD

Dilution
1 in 2000
in 10000
1 in 1000
in 1000
1 in 2000
1 in 1000
1 in 1000
1 in 2000
1 in 2000
1 in 2000
1 in 1000
1 in 200

Catalog#
14208-1-AP

Cytokeratin8
Cadherin E

Rb
Rb

52 KD
135 KD

1 in 10000
1 in 1000

ab53280
24-E-10

Cadherin N
GluD1

Rb
Rb

130 KD
45-55 KD

1 in 2000
1 in 2000

GTX112733
14299-1-AP

GluL
PHGDH

Rb
Rb

42 KD
57 KD

1 in 1000
1 in 1000

ab73593
ab211365

Aldolase
FBP1

Rb
Rb

40 KD
36 KD

1 in 1000
1 in 2000

#3188
ab109732

SNAI1
NAMPT
G6PD
Vimentin
PGD
NRF2

Rb
Rb
Rb
Rb
Rb
Rb

26 KD
56 KD
59 KD
54 KD
45 KD
110 KD

1 in 2000
1 in 250
1 in 1000
1 in 1000
1 in 1000
1 in 2000

GTX125918
ab45890
ab76598
ab92547
ab129199
ab137550

GSR
GPX4
GSS
GLS2

Rb
Rb
Rb
Rb

53 KD
17 KD
52 KD
66 KD

1 in 2000
1 in 2000
1 in10000
1 in 2000

18257-1-AP
ab125066
ab124811
ab113509

PGAM1
SOD1
GST
GSTP1

Rb
Rb
Rb
Rb

28 KD
20 KD
46 KD
23 KD

1 in 2000
1 in 2000
1 in 1000
1 in 1000

ab247037
10269-1-AP
#2625
GTX112695

GOT1
GOT2
Caspase 3

Rb
Rb
Rb

55KD
43 KD
35 KD

1 in 5000
1 in 2000
1 in 1000

ab239487
ab171739
#9662
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ab4694
ab154613
ab192876
3810T
ab70358
12855
400080
14681-1-AP
ab53121
ab7800

cleaved
Capspae3
PSAT1
ME1
TALDO1
IDH1
ASCT2
P53
SHMT1
SHMT2
TWIST1/2
TGFβ
SOX2
ZO-1
GCLC
MTHFD
SLC7a11 (xCT)
KLF4
GLP
G9A

Rb

17 KD

1 in 1000

#9664S

Rb
Rb
Rb
Rb
Rb
Rb
Rb
Rb
Rb
Rb
Ms
Rb
Rb
Rb
Rb
Rb
Rb
Rb

1 in 1000
1 in 1000
1 in 1000
1 in 1000
1 in 1000
1 in 2000
1 in 1000
1 in 1000
1 in 2000
1 in 1000
1 in 1000
1 in 2000
1 in 2000
1 in 1000
1 in 1000
1 in 1000
1 in 5000
1 in 1000

10501-1-AP
16619-1-AP
12378-1-AP
3997S
#5345S
10442-1-AP
14149-1-AP
11099-1-AP
GTX127310
ab179695
ab171380
21773-1-AP
12601-1-AP
10794-1-AP
#12691
11880-1-AP
ab231224
ab285050

Integrin β4

Rb

1:500,1000

21738-1-AP

CD44
PKM2
ATF4

Rb
Rb
Rb

37-45 KD
55-64 KD
38 KD
46 KD
49, 75 KD
53 KD
53 KD
55 KD
21 KD
44 KD
34 KD
230 KD
73 KD
101 KD
35 KD
50-60 KD
141 KD
160 KD
200240KD
80-95KD
58 KD
49 KD

1 in 2000
1 in 1000
1 in 1000

ER

Rb

68 KD

1:500,1000

PR
HER2

Rb
Rb

1 in 1000
1 in 1000

Rb
Rb
Rb

90,118 KD
185 KD
190-210
KD
56,66 KD
33,35 KD

15675-1-AP
15822-1-AP
#118155
NBP104936
#3153
#2165

1 in 1000
1 in 1000
1 in 500

21544-1-AP
22980-1-AP
13108-1-AP

Rb

62 KD

in in 500

11604-1-AP

ZEB1
PRODH
PYCR
ALDH1A4
(P5CDH)
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Appendix 2: List of primers
Primer name

Sequence

18S-Fw

TCAAGAACGAAAGTCGGAGGTT

18S-Rv

GGACATCTAAGGGCATCACAG

Asns-Fw

GCCTCCAACCGGTCTTGTC

Asns-Rv

CACACATGCTACAGGCGGAC

G6PD-Fw

GGGAAGAGTTGTACCAGGGTG

G6PD-Rv

TCTTCAGGTAGAAGGCCATCCC

Gclc-Fw

CACATCTACCACGCAGTCAAG

Gclc-Rv

AGGACACCAACATGTACTCCAC

Gclm-Fw

AGTTGACATGGCATGCTCCG

Glcm-Rv

TCCATCTTCAATCGGAGGCG

GLS1-Fw

CTCGGAGAGAAGGAGGTGAT

GLS1-Rv

ATCTCCAGTGTATGCGGCAA

GLS2-Fw

AGGGAAGGAGGAGAGGTTCG

GLS2-Rv

CCATGGCCGACAATGCAAAC

GluD-Fw

AGCTGGCCAAGAAGGGTTTT

GluD-Rv

GCATAGGTGTCAGCGATCCA

GluL- Rv

GGATGGGTGAACAGGTCAGG

GluL-Fw

GCGGAGAATGGGAGTAGAGC

Gpx4-Fw

CCGTCTGAGCCGCTTACTTA

GPx4-Rv

GGCTGAGAATTCGTGCATGG

Gsr-Fw

TGGCACTTGCGTGAATGTTG

Gsr-Rv

TGTTCAGGCGGCTCACATAG

Gss-Fw

CCAAAGCCTGGGAGCTCTAT

Gss-Rv

ACGGCACGCTGGTCAAATA

Gstp1-Fw

GCGGCAAATATGTCACCCTCA

Gstp2-Rv

GAAAGCTTTGCCTCCCTGGT

HIF1α-Fw

TTCTCTGCCAGTTTTCTGGG

HIF1α-Rv

ACTCTTTGCTTCGCCGAGAT

IDH1-Fw

TGCAAGGAGATGAAATGACACG

IDH1-Rv

TGGTGGCATCACGATTCTCT

ME1-Fw

GGGACCCGCATCTCAACAAG

ME1-Rv

TCGAAGTCAGAGTTCAGTCGT

MTHFD1-Fw

ATCCTGTCACTGCAAAGCCC

MTHFD1-Rv

CACCAGGGACGGGAGTGATA

N-Cadherin-Fw

AGGATGTGCACGAAGGACAG

N-Cadherin-Rv

CTTGAAATCTGCTGGCTCGC
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NAMPT-Fw

CTGTGGCGGGAATTGCTCTA

Nampt-Fw

CATTCAAGGAGATGGCGTGGA

NAMPT-Rv

GTCTTTCCCCCAAGCCGTTA

Nampt-Rv

CACCAGAACCGAAGGAGACA

Nqo1-Fw

ACGTCATTCTCTGGCCGATT

Nqo1-Rv

TCTCCTCCCAGACGGTTTCC

NRF2-Fw

AATTCCTCCCAATTCAGCCG

NRF2-Rv

TGTTTGGGAATGTGGGCAAC

P5cdh-fw

AACGCTGCTGGCAACTTCTA

P5cdh-Rv

CCTCCTGGCTTGTCATTGGT

P5cs-Fw

AGTCTCGCCCTGACTGTCTA

P5cs-rv

CCCACCTTTGAGCAACAAGC

PGD-Fw

TCCTCGACTCTGCTTCGTCT

PGD-Rv

GACTGTGCACCAACCACCTT

PGK1-Fw

TGCTGGAAAACCTCCGCTTT

PGK1-Rv

TGAGGCTCGGAAAGCATCAA

Phgdh-Fw

GGCCTCGGCAGAATTGGAA

Phgdh-Rv

TCAGGAGAGATGATGGGGTCA

Prodh-Fw

TGATGGTGGCTTCCCACAAC

Prodh-Rv

CGAAGCACACCTGACCATCA

Pycr-Fw

CGCGTGGCGAATGCAAG

Pycr-Rv

GCTGGCCATTATCTTGTGTGC

Shmt1-Fw

GGAACAGACGTTTACGGCCA

Shmt1-Rv

GTCTGCCATTGCACTGGTTC

Shmt2-Fw

GCCTCCTGTAGCGATGGTAT

Shmt2-Rv

GACCAGCTGACCACATCTC

Slc7a11-Fw

TCTGGGTGGAACTGCTCGTA

Slc7a11-Rv

GTTCCAGGATGTAGCGTCCA

Snai1-Fw

GTCTGCACGACCTGTGGAAA

Snai1-Rv

GGTCAGCAAAAGCACGGTTG

TALDO1-Fw

ATCATCAACCTGGGAGGGGA

TALDO1-Rv

GTCATGTTGCAGTGGATGCC

Twist1-Fw

GTCCCACTAGCAGCGGAG

Twist1-Rv

CCAGAGTCTCTAGACTGTCCAT

Zeb1-Fw

GTGTAAGCGCAGAAAGCAGG

Zeb1-Rv

TGGAGTTTGTCTTCATCATCGGA
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Appendix 3: List of drug and reagents
Reagents
30 % H2O2
CB-839 (Telaglenastat)
BPTE
CBR5884
L-Buthionine-sulfoximine
CellRox Deep Red
MitoSox Orange

Company
Fisher
Scientific
Selleckchem
Sigma
Millipore Sigma
Millipore Sigma
Life
Technologies
Life
Technologies
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Dilution
500 µM, 1 mM

Catalog#
H325-500

10 µM, 20 µM
10 µM, 20 µM
30 µM, 60 µM
50 µM, 100 µM
1:1000

S7655
SML0601-25MG
SML1656-5MG
B2515
C10422

1:1000

M36008
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